<!DOCTYPE html>
<html lang="en" dir="ltr" class="client-nojs">
<head>
<meta charset="UTF-8" />
<title>Guillain–Barré syndrome - Wikipedia, the free encyclopedia</title>
<meta name="generator" content="MediaWiki 1.26wmf13" />
<link rel="alternate" href="android-app://org.wikipedia/http/en.m.wikipedia.org/wiki/Guillain%E2%80%93Barr%C3%A9_syndrome" />
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit" />
<link rel="edit" title="Edit this page" href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit" />
<link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png" />
<link rel="shortcut icon" href="/static/favicon/wikipedia.ico" />
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd" />
<link rel="alternate" hreflang="x-default" href="/wiki/Guillain%E2%80%93Barr%C3%A9_syndrome" />
<link rel="copyright" href="//creativecommons.org/licenses/by-sa/3.0/" />
<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=atom" />
<link rel="canonical" href="https://en.wikipedia.org/wiki/Guillain%E2%80%93Barr%C3%A9_syndrome" />
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=ext.uls.nojs%7Cext.visualEditor.viewPageTarget.noscript%7Cext.wikihiero%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.sectionAnchor%7Cmediawiki.skinning.interface%7Cmediawiki.ui.button%7Cskins.vector.styles%7Cwikibase.client.init&amp;only=styles&amp;skin=vector&amp;*" />
<meta name="ResourceLoaderDynamicStyles" content="" />
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=site&amp;only=styles&amp;skin=vector&amp;*" />
<style>a:lang(ar),a:lang(kk-arab),a:lang(mzn),a:lang(ps),a:lang(ur){text-decoration:none}
/* cache key: global:resourceloader:filter:minify-css:7:de1ab5287c9076b96eedd3f97a84a7b6 */</style>
<script src="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=startup&amp;only=scripts&amp;skin=vector&amp;*"></script>
<script>if(window.mw){
mw.config.set({"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Guillain–Barré_syndrome","wgTitle":"Guillain–Barré syndrome","wgCurRevisionId":670975682,"wgRevisionId":670975682,"wgArticleId":12800708,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["CS1 maint: Explicit use of et al.","Articles with contributors link","Articles with DMOZ links","Articles that use a Medicine navs subtemplate","Autoimmune diseases","Syndromes","Neurological disorders","Cytomegalovirus-associated diseases"],"wgBreakFrames":false,"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgMonthNamesShort":["","Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"wgRelevantPageName":"Guillain–Barré_syndrome","wgRelevantArticleId":12800708,"wgIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgRedirectedFrom":"Acute_idiopathic_polyneuritis","wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wikilove-recipient":"","wikilove-anon":0,"wgPoweredByHHVM":true,"wgWikiEditorEnabledModules":{"toolbar":true,"dialogs":true,"hidesig":true,"preview":false,"publish":false},"wgBetaFeaturesFeatures":[],"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","usePageImages":true,"usePageDescriptions":true},"wgGatherShouldShowTutorial":true,"wgGatherPageImageThumbnail":"//upload.wikimedia.org/wikipedia/commons/thumb/5/52/Spirodoc_FVC.jpg/100px-Spirodoc_FVC.jpg","wgULSAcceptLanguageList":[],"wgULSCurrentAutonym":"English","wgFlaggedRevsParams":{"tags":{"status":{"levels":1,"quality":2,"pristine":3}}},"wgStableRevisionId":null,"wgCategoryTreePageCategoryOptions":"{\"mode\":0,\"hideprefix\":20,\"showcount\":true,\"namespaces\":false}","wgNoticeProject":"wikipedia","wgInternalRedirectTargetUrl":"/wiki/Guillain%E2%80%93Barr%C3%A9_syndrome","wgWikibaseItemId":"Q205214"});
}</script><script>if(window.mw){
mw.loader.implement("user.options",function($,jQuery){mw.user.options.set({"variant":"en"});});
/* cache key: global:resourceloader:filter:minify-js:7:b2706269305541eba923c165462b22c4 */
}</script>
<script>if(window.mw){
mw.loader.implement("user.tokens",function($,jQuery){mw.user.tokens.set({"editToken":"+\\","patrolToken":"+\\","watchToken":"+\\"});});
}</script>
<script>if(window.mw){
mw.loader.load(["mediawiki.action.view.redirect","mediawiki.page.startup","mediawiki.legacy.wikibits","mediawiki.legacy.ajax","ext.centralauth.centralautologin","mmv.head","ext.imageMetrics.head","ext.visualEditor.viewPageTarget.init","ext.uls.init","ext.uls.interface","ext.centralNotice.bannerController","skins.vector.js"]);
}</script>
<link rel="dns-prefetch" href="//meta.wikimedia.org" />
<!--[if lt IE 7]><style type="text/css">body{behavior:url("/w/static/1.26wmf13/skins/Vector/csshover.min.htc")}</style><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Guillain–Barré_syndrome skin-vector action-view">
		<div id="mw-page-base" class="noprint"></div>
		<div id="mw-head-base" class="noprint"></div>
		<div id="content" class="mw-body" role="main">
			<a id="top"></a>

							<div id="siteNotice"><!-- CentralNotice --></div>
						<div class="mw-indicators">
</div>
			<h1 id="firstHeading" class="firstHeading" lang="en">Guillain–Barré syndrome</h1>
									<div id="bodyContent" class="mw-body-content">
									<div id="siteSub">From Wikipedia, the free encyclopedia</div>
								<div id="contentSub"><span class="mw-redirectedfrom">  (Redirected from <a href="/w/index.php?title=Acute_idiopathic_polyneuritis&amp;redirect=no" title="Acute idiopathic polyneuritis">Acute idiopathic polyneuritis</a>)</span></div>
												<div id="jump-to-nav" class="mw-jump">
					Jump to:					<a href="#mw-head">navigation</a>, 					<a href="#p-search">search</a>
				</div>
				<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><table class="infobox" style="width:22em">
<tr>
<th colspan="2" style="text-align:center;font-size:125%;font-weight:bold;background-color: lightgrey">Guillain–Barré syndrome</th>
</tr>
<tr>
<td colspan="2" style="text-align:center"><a href="/wiki/File:Spirodoc_FVC.jpg" class="image"><img alt="Spirodoc FVC.jpg" src="//upload.wikimedia.org/wikipedia/commons/thumb/5/52/Spirodoc_FVC.jpg/230px-Spirodoc_FVC.jpg" width="230" height="230" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/5/52/Spirodoc_FVC.jpg/345px-Spirodoc_FVC.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/5/52/Spirodoc_FVC.jpg/460px-Spirodoc_FVC.jpg 2x" data-file-width="512" data-file-height="512" /></a>
<div>A handheld <a href="/wiki/Spirometry" title="Spirometry">spirometry</a> device, which can be used to anticipate breathing complications of Guillain-Barré syndrome</div>
</td>
</tr>
<tr>
<th colspan="2" style="text-align:center">Classification and external resources</th>
</tr>
<tr>
<th scope="row"><a href="/wiki/Specialty_(medicine)" title="Specialty (medicine)">Specialty</a></th>
<td><a href="/wiki/Neurology" title="Neurology">Neurology</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/ICD-10" title="ICD-10">10</a></th>
<td><a rel="nofollow" class="external text" href="http://apps.who.int/classifications/icd10/browse/2015/en#/G61.0">G61.0</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/List_of_ICD-9_codes" title="List of ICD-9 codes">9-CM</a></th>
<td><a rel="nofollow" class="external text" href="http://www.icd9data.com/getICD9Code.ashx?icd9=357.0">357.0</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/OMIM" title="OMIM" class="mw-redirect">OMIM</a></th>
<td><a rel="nofollow" class="external text" href="http://omim.org/entry/139393">139393</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Diseases_Database" title="Diseases Database">DiseasesDB</a></th>
<td><a rel="nofollow" class="external text" href="http://www.diseasesdatabase.com/ddb5465.htm">5465</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/MedlinePlus" title="MedlinePlus">MedlinePlus</a></th>
<td><a rel="nofollow" class="external text" href="http://www.nlm.nih.gov/medlineplus/ency/article/000684.htm">000684</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/EMedicine" title="EMedicine">eMedicine</a></th>
<td><a rel="nofollow" class="external text" href="http://www.emedicine.com/emerg/topic222.htm">emerg/222</a> <a rel="nofollow" class="external text" href="http://www.emedicine.com/neuro/topic7.htm#">neuro/7</a> <a rel="nofollow" class="external text" href="http://www.emedicine.com/pmr/topic48.htm#">pmr/48</a> <a rel="nofollow" class="external text" href="http://www.emedicine.com/neuro/topic598.htm#">neuro/598</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Patient_UK" title="Patient UK">Patient UK</a></th>
<td><a rel="nofollow" class="external text" href="http://patient.info/doctor/guillain-barre-syndrome-pro">Guillain–Barré syndrome</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Medical_Subject_Headings" title="Medical Subject Headings">MeSH</a></th>
<td><a rel="nofollow" class="external text" href="//www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&amp;term=D020275">D020275</a></td>
</tr>
</table>
<p><b>Guillain–Barré syndrome</b> (<b>GBS</b>), also known as <b>Guillain–Barré–Strohl syndrome</b> or <b>Landry's paralysis</b>, is a rapid-onset muscle weakness as a result of damage to the <a href="/wiki/Peripheral_nervous_system" title="Peripheral nervous system">peripheral nervous system</a>. Many experience changes in sensation or develop pain, followed by muscle weakness beginning in the feet and hands. The symptoms develop over half a day to two weeks. During the acute phase, the disorder can be life-threatening with about a quarter developing weakness of the breathing muscles and requiring admission to <a href="/wiki/Intensive_care_unit" title="Intensive care unit">intensive care unit</a> for <a href="/wiki/Mechanical_ventilation" title="Mechanical ventilation">mechanical ventilation</a>. Some are affected by <a href="/wiki/Dysautonomia" title="Dysautonomia">changes in the function</a> of the <a href="/wiki/Autonomic_nervous_system" title="Autonomic nervous system">autonomic nervous system</a>, which can lead to dangerous abnormalities in <a href="/wiki/Heart_rate" title="Heart rate">heart rate</a> and <a href="/wiki/Blood_pressure" title="Blood pressure">blood pressure</a>.</p>
<p>This autoimmune disease is caused by the body's own immune system, which mistakenly begins to attack the peripheral nerves, damaging their myelin insulation. Sometimes this immune dysfunction is triggered by an infection. The diagnosis is usually made on based on the signs and symptoms, through the exclusion of alternative causes, and supported by tests such as <a href="/wiki/Nerve_conduction_study" title="Nerve conduction study">nerve conduction studies</a> and examination of the <a href="/wiki/Cerebrospinal_fluid" title="Cerebrospinal fluid">cerebrospinal fluid</a>. Various classifications exist, depending on the areas of weakness, results of nerve conduction studies, and the presence of <a href="/wiki/Antiganglioside_antibodies" title="Antiganglioside antibodies">antiganglioside antibodies</a>. It is classified as an acute <a href="/wiki/Polyneuropathy" title="Polyneuropathy">polyneuropathy</a>.</p>
<p>In those with severe weakness, prompt treatment with <a href="/wiki/Intravenous_immunoglobulin" title="Intravenous immunoglobulin">intravenous immunoglobulins</a> or <a href="/wiki/Plasmapheresis" title="Plasmapheresis">plasmapheresis</a>, together with supportive care, will lead to good recovery in the majority. Some may experience ongoing difficulty with walking, painful symptoms, and some require long-term breathing support. Guillain–Barré syndrome is rare, at one to two cases per 100,000 people every year. The syndrome is named after the French physicians <a href="/wiki/Georges_Guillain" title="Georges Guillain">Georges Guillain</a> and <a href="/wiki/Jean_Alexandre_Barr%C3%A9" title="Jean Alexandre Barré">Jean Alexandre Barré</a>, who described it with <a href="/wiki/Andr%C3%A9_Strohl" title="André Strohl">André Strohl</a> in 1916.</p>
<p></p>
<div id="toc" class="toc">
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Signs_and_symptoms"><span class="tocnumber">1</span> <span class="toctext">Signs and symptoms</span></a>
<ul>
<li class="toclevel-2 tocsection-2"><a href="#Respiratory_failure"><span class="tocnumber">1.1</span> <span class="toctext">Respiratory failure</span></a></li>
<li class="toclevel-2 tocsection-3"><a href="#Autonomic_dysfunction"><span class="tocnumber">1.2</span> <span class="toctext">Autonomic dysfunction</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-4"><a href="#Causes"><span class="tocnumber">2</span> <span class="toctext">Causes</span></a></li>
<li class="toclevel-1 tocsection-5"><a href="#Mechanism"><span class="tocnumber">3</span> <span class="toctext">Mechanism</span></a></li>
<li class="toclevel-1 tocsection-6"><a href="#Diagnosis"><span class="tocnumber">4</span> <span class="toctext">Diagnosis</span></a>
<ul>
<li class="toclevel-2 tocsection-7"><a href="#Spinal_fluid"><span class="tocnumber">4.1</span> <span class="toctext">Spinal fluid</span></a></li>
<li class="toclevel-2 tocsection-8"><a href="#Neurophysiology"><span class="tocnumber">4.2</span> <span class="toctext">Neurophysiology</span></a></li>
<li class="toclevel-2 tocsection-9"><a href="#Clinical_subtypes"><span class="tocnumber">4.3</span> <span class="toctext">Clinical subtypes</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-10"><a href="#Treatment"><span class="tocnumber">5</span> <span class="toctext">Treatment</span></a>
<ul>
<li class="toclevel-2 tocsection-11"><a href="#Immunotherapy"><span class="tocnumber">5.1</span> <span class="toctext">Immunotherapy</span></a></li>
<li class="toclevel-2 tocsection-12"><a href="#Pain"><span class="tocnumber">5.2</span> <span class="toctext">Pain</span></a></li>
<li class="toclevel-2 tocsection-13"><a href="#Rehabilitation"><span class="tocnumber">5.3</span> <span class="toctext">Rehabilitation</span></a></li>
<li class="toclevel-2 tocsection-14"><a href="#Respiratory_failure_2"><span class="tocnumber">5.4</span> <span class="toctext">Respiratory failure</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-15"><a href="#Prognosis"><span class="tocnumber">6</span> <span class="toctext">Prognosis</span></a></li>
<li class="toclevel-1 tocsection-16"><a href="#Epidemiology"><span class="tocnumber">7</span> <span class="toctext">Epidemiology</span></a></li>
<li class="toclevel-1 tocsection-17"><a href="#History"><span class="tocnumber">8</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1 tocsection-18"><a href="#Research_directions"><span class="tocnumber">9</span> <span class="toctext">Research directions</span></a></li>
<li class="toclevel-1 tocsection-19"><a href="#See_also"><span class="tocnumber">10</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1 tocsection-20"><a href="#References"><span class="tocnumber">11</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-21"><a href="#Further_reading"><span class="tocnumber">12</span> <span class="toctext">Further reading</span></a></li>
<li class="toclevel-1 tocsection-22"><a href="#External_links"><span class="tocnumber">13</span> <span class="toctext">External links</span></a></li>
</ul>
</div>
<p></p>
<h2><span class="mw-headline" id="Signs_and_symptoms">Signs and symptoms</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=1" title="Edit section: Signs and symptoms">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>The first symptoms of Guillain–Barré syndrome (<small>French pronunciation:&#160;​</small><span title="Representation in the International Phonetic Alphabet (IPA)" class="IPA"><a href="/wiki/Help:IPA_for_French" title="Help:IPA for French">[ɡiˈlɛ̃ baˈʁe]</a></span>, <span class="nowrap"><small>English pronunciation:</small> <span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English" title="Help:IPA for English">/<span style="border-bottom:1px dotted"><span title="'g' in 'guy'">ɡ</span><span title="/iː/ long 'e' in 'bead'">iː</span><span title="/ˈ/ primary stress follows">ˈ</span><span title="/j/ 'y' in 'yes'">j</span><span title="/æ/ short 'a' in 'bad'">æ</span><span title="'n' in 'no'">n</span><span title="'b' in 'buy'">b</span><span title="/ɑr/ 'ar' in 'bard'">ɑr</span><span title="/ˈ/ primary stress follows">ˈ</span><span title="/eɪ/ long 'a' in 'base'">eɪ</span></span>/</a></span></span>) are numbness, <a href="/wiki/Paresthesia" title="Paresthesia">tingling</a>, and pain, alone or in combination. This is followed by weakness of the legs and arms that affects both sides equally and worsening over time.<sup id="cite_ref-NEJM2012_1-0" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup> The weakness can take half a day to over two weeks to reach maximum severity, and then becomes steady.<sup id="cite_ref-NEJM2012_1-1" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup> In one in five people the weakness continues to progress for as long as four weeks.<sup id="cite_ref-NatRevNeurol2014_2-0" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup> The muscles of the neck may also be affected, and about half experience involvement of the <a href="/wiki/Cranial_nerves" title="Cranial nerves">cranial nerves</a>, which supply the head and face; this may lead to <a href="/wiki/Facial_weakness" title="Facial weakness">weakness of the muscles of the face</a>, <a href="/wiki/Dysphagia" title="Dysphagia">swallowing difficulties</a> and sometimes <a href="/wiki/Ophthalmoparesis" title="Ophthalmoparesis">weakness of the eye muscles</a>.<sup id="cite_ref-NatRevNeurol2014_2-1" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup> In 8% the weakness <a href="/wiki/Paraplegia" title="Paraplegia">affects only the legs</a> (paraplegia or paraparesis).<sup id="cite_ref-NatRevNeurol2014_2-2" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup> Involvement of the muscles that control the bladder and anus is unusual.<sup id="cite_ref-NEJM2012_1-2" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup> In total, about a third of people with Guillain–Barré syndrome continue to be able to walk.<sup id="cite_ref-NatRevNeurol2014_2-3" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup> Once the weakness has stopped progressing, it persists at a stable level ("plateau phase") before improvement occur. The plateau phase can take between two days and six months, but the most common duration is a week.<sup id="cite_ref-NatRevNeurol2014_2-4" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup> Pain-related symptoms affect more than half, and include <a href="/wiki/Back_pain" title="Back pain">back pain</a>, painful tingling, <a href="/wiki/Myalgia" title="Myalgia">muscle pain</a> and <a href="/wiki/Meningism" title="Meningism">pain in the head and neck relating to irritation of the lining of the brain</a>.<sup id="cite_ref-NatRevNeurol2014_2-5" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup></p>
<p>Many people with Guillain–Barré syndrome have experienced the signs and symptoms of an infection in the 3–6 weeks prior to the onset of the neurological symptoms. This may consist of <a href="/wiki/Upper_respiratory_tract_infection" title="Upper respiratory tract infection">upper respiratory tract infection</a> (rhinitis, sore throat) or <a href="/wiki/Diarrhea" title="Diarrhea">diarrhea</a>.<sup id="cite_ref-NEJM2012_1-3" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup></p>
<p>In children, particularly those younger than six years old, the diagnosis can be difficult and the condition is often initially mistaken (sometimes for up to two weeks) for other causes of pains and difficulty walking, such as viral infections,<sup id="cite_ref-NatRevNeurol2014_2-6" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup> or bone and joint problems.<sup id="cite_ref-Ryan2013_3-0" class="reference"><a href="#cite_note-Ryan2013-3"><span>[</span>3<span>]</span></a></sup></p>
<p>On <a href="/wiki/Neurological_examination" title="Neurological examination">neurological examination</a>, characteristic features are the reduced power and reduced or absent <a href="/wiki/Stretch_reflex" title="Stretch reflex">tendon reflexes</a> (<a href="/wiki/Hyporeflexia" title="Hyporeflexia">hypo- or areflexia</a>, respectively). However, a small proportion has normal reflexes in affected limbs before developing areflexia, and some may have exaggerated reflexes.<sup id="cite_ref-NatRevNeurol2014_2-7" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup> In the "Miller Fisher variant" subtype of Guillain–Barré syndrome (see below), <a href="/wiki/Ophthalmoparesis" title="Ophthalmoparesis">weakness of the eye muscles</a> (ophthalmoplegia) is more pronounced and may occur together with <a href="/wiki/Ataxia" title="Ataxia">abnormalities in coordination</a> (ataxia).<sup id="cite_ref-NEJM2012_1-4" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup> The <a href="/wiki/Altered_level_of_consciousness" title="Altered level of consciousness">level of consciousness</a> is normally unaffected in Guillain–Barré syndrome, but the <a href="/wiki/Bickerstaff%27s_encephalitis" title="Bickerstaff's encephalitis">Bickerstaff brainstem encephalitis</a> subtype may feature drowsiness, sleepiness, or coma.<sup id="cite_ref-vanDoorn2008_4-0" class="reference"><a href="#cite_note-vanDoorn2008-4"><span>[</span>4<span>]</span></a></sup><sup id="cite_ref-Shahrizaila2013_5-0" class="reference"><a href="#cite_note-Shahrizaila2013-5"><span>[</span>5<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Respiratory_failure">Respiratory failure</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=2" title="Edit section: Respiratory failure">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>A quarter of all people with Guillain–Barré syndrome develop weakness of the breathing muscles leading to <a href="/wiki/Respiratory_failure" title="Respiratory failure">respiratory failure</a>, the inability to breathe adequately to maintain healthy levels of <a href="/wiki/Oxygen" title="Oxygen">oxygen</a> and/or <a href="/wiki/Carbon_dioxide" title="Carbon dioxide">carbon dioxide</a> in the blood.<sup id="cite_ref-NEJM2012_1-5" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-NatRevNeurol2014_2-8" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup><sup id="cite_ref-vanDoorn2010_6-0" class="reference"><a href="#cite_note-vanDoorn2010-6"><span>[</span>6<span>]</span></a></sup> This life-threatening scenario is complicated by other medical problems such as <a href="/wiki/Pneumonia" title="Pneumonia">pneumonia</a>, <a href="/wiki/Sepsis" title="Sepsis">severe infections</a>, <a href="/wiki/Pulmonary_embolism" title="Pulmonary embolism">blood clots in the lungs</a> and <a href="/wiki/Gastrointestinal_hemorrhage" title="Gastrointestinal hemorrhage" class="mw-redirect">bleeding in the digestive tract</a> in 60% of those who require artificial ventilation.<sup id="cite_ref-NEJM2012_1-6" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Autonomic_dysfunction">Autonomic dysfunction</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=3" title="Edit section: Autonomic dysfunction">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The <a href="/wiki/Autonomic_nervous_system" title="Autonomic nervous system">autonomic or involuntary nervous system</a>, which is involved in the control of body functions such as <a href="/wiki/Heart_rate" title="Heart rate">heart rate</a> and <a href="/wiki/Blood_pressure" title="Blood pressure">blood pressure</a>, is affected in two thirds of people with Guillain–Barré syndrome, but the impact is variable.<sup id="cite_ref-NatRevNeurol2014_2-9" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup> Twenty percent may experience severe blood pressure fluctuations and <a href="/wiki/Cardiac_dysrhythmia" title="Cardiac dysrhythmia" class="mw-redirect">irregularities in the heart beat</a>, sometimes to the point that the <a href="/wiki/Asystole" title="Asystole">heart beat stops</a> and requiring <a href="/wiki/Artificial_cardiac_pacemaker" title="Artificial cardiac pacemaker">pacemaker-based treatment</a>.<sup id="cite_ref-NEJM2012_1-7" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup> Other associated problems are abnormalities in <a href="/wiki/Perspiration" title="Perspiration">perspiration</a> and changes in the <a href="/wiki/Pupillary_response" title="Pupillary response">reactivity of the pupils</a>.<sup id="cite_ref-vanDoorn2008_4-1" class="reference"><a href="#cite_note-vanDoorn2008-4"><span>[</span>4<span>]</span></a></sup> Autonomic nervous system involvement can affect even those who do not have severe muscle weakness.<sup id="cite_ref-vanDoorn2008_4-2" class="reference"><a href="#cite_note-vanDoorn2008-4"><span>[</span>4<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Causes">Causes</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=4" title="Edit section: Causes">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:ARS_Campylobacter_jejuni.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/d/df/ARS_Campylobacter_jejuni.jpg/220px-ARS_Campylobacter_jejuni.jpg" width="220" height="293" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/d/df/ARS_Campylobacter_jejuni.jpg/330px-ARS_Campylobacter_jejuni.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/df/ARS_Campylobacter_jejuni.jpg/440px-ARS_Campylobacter_jejuni.jpg 2x" data-file-width="2025" data-file-height="2700" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:ARS_Campylobacter_jejuni.jpg" class="internal" title="Enlarge"></a></div>
A <a href="/wiki/Scanning_electron_microscope" title="Scanning electron microscope">scanning electron microscope</a>-derived image of <i>Campylobacter jejuni</i>, which triggers about 30% of cases of Guillain-Barré syndrome.</div>
</div>
</div>
<p>Two thirds of people with Guillain–Barré syndrome have experienced an infection before the onset of the condition. Most commonly these are episodes of <a href="/wiki/Gastroenteritis" title="Gastroenteritis">gastroenteritis</a> or a <a href="/wiki/Respiratory_tract_infection" title="Respiratory tract infection">respiratory tract infection</a>. In many cases the exact nature of the infection can be confirmed.<sup id="cite_ref-NatRevNeurol2014_2-10" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup> Approximately 30% of cases are provoked by <i><a href="/wiki/Campylobacter_jejuni" title="Campylobacter jejuni">Campylobacter jejuni</a></i> bacteria, which cause diarrhea. A further 10% cases are attributable to <a href="/wiki/Human_cytomegalovirus" title="Human cytomegalovirus">cytomegalovirus</a> (CMV, HHV-5). Despite this, only very few people with <i>Campylobacter</i> or CMV infections develop Guillain–Barré syndrome (0.25–0.65 per 1000 and 0.6–2.2 per 1000 episodes, respectively).<sup id="cite_ref-NEJM2012_1-8" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup> The strain of <i>Campylobacter</i> involved may determine the risk of GBS; different forms of the bacteria have different <a href="/wiki/Lipopolysaccharide" title="Lipopolysaccharide">lipopolysaccharides</a> on their surface, and some may induce illness (see below) while others will not.<sup id="cite_ref-NatRevNeurol2014_2-11" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup></p>
<p>Links between other infections and GBS are less certain. Two other herpesviruses (<a href="/wiki/Epstein%E2%80%93Barr_virus" title="Epstein–Barr virus">Epstein–Barr virus</a>/HHV-4 and <a href="/wiki/Varicella_zoster_virus" title="Varicella zoster virus">varicella zoster virus</a>/HHV-3) and the bacterium <i><a href="/wiki/Mycoplasma_pneumoniae" title="Mycoplasma pneumoniae">Mycoplasma pneumoniae</a></i> have been associated with GBS.<sup id="cite_ref-NEJM2012_1-9" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup> The tropical viral infection <a href="/wiki/Dengue_fever" title="Dengue fever">dengue fever</a> has been associated with episodes of GBS.<sup id="cite_ref-Carod2013_7-0" class="reference"><a href="#cite_note-Carod2013-7"><span>[</span>7<span>]</span></a></sup> Previous <a href="/wiki/Hepatitis_E_virus" title="Hepatitis E virus">hepatitis E virus</a> infection has been found to be more common in people with Guillain–Barré syndrome.<sup id="cite_ref-NatRevNeurol2014_2-12" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup><sup id="cite_ref-Eldar2014_8-0" class="reference"><a href="#cite_note-Eldar2014-8"><span>[</span>8<span>]</span></a></sup></p>
<p>Some cases may be triggered by the <a href="/wiki/Influenza_virus" title="Influenza virus" class="mw-redirect">influenza virus</a> and potentially <a href="/wiki/Influenza_vaccine" title="Influenza vaccine">influenza vaccine</a>. An increased incidence of Guillain–Barré syndrome followed influenza immunization that followed the <a href="/wiki/1976_swine_flu_outbreak" title="1976 swine flu outbreak">1976 swine flu outbreak</a> (H1N1&#160;A/NJ/76); 8.8 cases per million recipients developed the complication. Since then, close monitoring of cases attributable to vaccination has demonstrated that influenza itself can induce GBS. Small increases in incidence have been observed in subsequent vaccination campaigns, but not to the same extent.<sup id="cite_ref-Lehmann2010_9-0" class="reference"><a href="#cite_note-Lehmann2010-9"><span>[</span>9<span>]</span></a></sup> The <a href="/wiki/2009_flu_pandemic_vaccine" title="2009 flu pandemic vaccine">2009 flu pandemic vaccine</a> (against <a href="/wiki/Pandemic_H1N1/09_virus" title="Pandemic H1N1/09 virus">pandemic swine flu virus H1N1/PDM09</a>) did not cause a significant increase in cases.<sup id="cite_ref-NEJM2012_1-10" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup> The benefits from vaccination to prevent influenza outweigh the small risks of GBS after vaccination.<sup id="cite_ref-Rinaldi2013_10-0" class="reference"><a href="#cite_note-Rinaldi2013-10"><span>[</span>10<span>]</span></a></sup> Even those who have previously experienced Guillain–Barré syndrome are considered safe to receive the vaccine in the future.<sup id="cite_ref-NatRevNeurol2014_2-13" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup> Other vaccines, such as those against <a href="/wiki/Poliomyelitis" title="Poliomyelitis">poliomyelitis</a>, <a href="/wiki/Tetanus" title="Tetanus">tetanus</a> or <a href="/wiki/Measles" title="Measles">measles</a>, have not been associated with a risk of GBS.<sup id="cite_ref-Ryan2013_3-1" class="reference"><a href="#cite_note-Ryan2013-3"><span>[</span>3<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Mechanism">Mechanism</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=5" title="Edit section: Mechanism">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<table class="infobox">
<caption>Structure of a typical neuron</caption>
<tr>
<th style="background-color: #d0d0d0;">Neuron</th>
</tr>
<tr style="text-align: center">
<td>
<div style="position: relative;"><a href="/wiki/File:Neuron_Hand-tuned.svg" class="image"><img alt="At one end of an elongated structure is a branching mass. At the centre of this mass is the nucleus and the branches are dendrites. A thick axon trails away from the mass, ending with further branching which are labeled as axon terminals. Along the axon are a number of protuberances labeled as myelin sheaths." src="//upload.wikimedia.org/wikipedia/commons/thumb/b/bc/Neuron_Hand-tuned.svg/400px-Neuron_Hand-tuned.svg.png" width="400" height="215" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/bc/Neuron_Hand-tuned.svg/600px-Neuron_Hand-tuned.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/bc/Neuron_Hand-tuned.svg/800px-Neuron_Hand-tuned.svg.png 2x" data-file-width="1179" data-file-height="634" /></a>
<div style="position:absolute;text-align:center;left:50px;top:2px"><a href="/wiki/Dendrite" title="Dendrite">Dendrite</a></div>
<div style="position:absolute;text-align:center;left:135px;top:60px"><a href="/wiki/Perikaryon" title="Perikaryon">Soma</a></div>
<div style="position:absolute;text-align:center;left:189px;top:116px"><a href="/wiki/Axon" title="Axon">Axon</a></div>
<div style="position:absolute;text-align:center;left:13px;top:197px"><a href="/wiki/Cell_nucleus" title="Cell nucleus">Nucleus</a></div>
<div style="position:absolute;text-align:center;left:226px;top:38px"><a href="/wiki/Myelin_sheath_gap" title="Myelin sheath gap" class="mw-redirect">Node of<br />
Ranvier</a></div>
<div style="position:absolute;text-align:center;left:319px;top:0px"><a href="/wiki/Axon_terminal" title="Axon terminal">Axon terminal</a></div>
<div style="position:absolute;text-align:center;left:306px;top:161px"><a href="/wiki/Schwann_cell" title="Schwann cell">Schwann cell</a></div>
<div style="position:absolute;text-align:center;left:220px;top:187px"><a href="/wiki/Myelin" title="Myelin">Myelin sheath</a></div>
</div>
</td>
</tr>
</table>
<p>The nerve dysfunction in Guillain–Barré syndrome is caused by an immune attack on the nerve cells of the peripheral nervous system and their support structures. The nerve cells have their body (the soma) in the <a href="/wiki/Spinal_cord" title="Spinal cord">spinal cord</a> and a long projection (the <a href="/wiki/Axon" title="Axon">axon</a>) that carries <a href="/wiki/Action_potential" title="Action potential">electrical nerve impulses</a> to the <a href="/wiki/Neuromuscular_junction" title="Neuromuscular junction">neuromuscular junction</a> where the impulse is transferred to the muscle. Axons are wrapped in a sheath of <a href="/wiki/Schwann_cell" title="Schwann cell">Schwann cells</a> that contain <a href="/wiki/Myelin" title="Myelin">myelin</a>. Between Schwann cells are gaps (<a href="/wiki/Node_of_Ranvier" title="Node of Ranvier">nodes of Ranvier</a>) where the axon is exposed.<sup id="cite_ref-NEJM2012_1-11" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup> Different types of Guillain–Barré syndrome feature different types of immune attack. The demyelinating variant (AIDP, see below) features damage to the myelin sheath by <a href="/wiki/White_blood_cell" title="White blood cell">white blood cells</a> (<a href="/wiki/T_cell" title="T cell">T lymphocytes</a> and <a href="/wiki/Macrophage" title="Macrophage">macrophages</a>); this process is preceded by activation of a group of blood proteins known as <a href="/wiki/Complement_system" title="Complement system">complement</a>. In contrast, the axonal variant is mediated by <a href="/wiki/Immunoglobulin_G" title="Immunoglobulin G">IgG antibodies</a> and complement directly against the <a href="/wiki/Axolemma" title="Axolemma">cell membrane covering the axon</a> without lymphocyte involvement.<sup id="cite_ref-NEJM2012_1-12" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup></p>
<p>Various antibodies directed at nerve cells have been reported in Guillain–Barré syndrome. In the axonal subtype, these antibodies have been shown to bind to <a href="/wiki/Ganglioside" title="Ganglioside">gangliosides</a>, a group of substances found in peripheral nerves. A ganglioside is a molecule consisting of <a href="/wiki/Ceramide" title="Ceramide">ceramide</a> bound to a small group of <a href="/wiki/Hexose" title="Hexose">hexose</a>-type sugars and containing various numbers of <a href="/wiki/N-Acetylneuraminic_acid" title="N-Acetylneuraminic acid"><i>N</i>-acetylneuraminic acid</a> groups. The key four gangliosides <a href="/wiki/Antiganglioside_antibodies" title="Antiganglioside antibodies">against which antibodies have been described</a> are <a href="/wiki/GM1" title="GM1">GM1</a>, GD1a, GT1a, and GQ1b, with different anti-ganglioside antibodies being associated with particular features; for instance, GQ1b antibodies have been linked with Miller Fisher variant GBS and related forms including Bickerstaff encephalitis.<sup id="cite_ref-NEJM2012_1-13" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup> The production of these antibodies after an infection is probably the result of <a href="/wiki/Molecular_mimicry" title="Molecular mimicry">molecular mimicry</a>, where the immune system is reacting to microbial substances but the resultant antibodies also react with <a href="/wiki/Epitope" title="Epitope">epitopes</a> occurring naturally in the body.<sup id="cite_ref-NEJM2012_1-14" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-Kuwabara2013_11-0" class="reference"><a href="#cite_note-Kuwabara2013-11"><span>[</span>11<span>]</span></a></sup> After a <i>Campylobacter</i> infection, the body produces antibodies of the <a href="/wiki/Immunoglobulin_A" title="Immunoglobulin A">IgA</a> class; only a small proportion of people also produce IgG antibodies against bacterial substance cell wall substances (e.g. <a href="/wiki/Lipopolysaccharide" title="Lipopolysaccharide">lipooligosaccharides</a>) that crossreact with human nerve cell gangliosides. It is not currently know how this process escapes <a href="/wiki/Central_tolerance" title="Central tolerance">central tolerance</a> to gangliosides, which is meant to suppress the production of antibodies against the body's own substances.<sup id="cite_ref-WillisonGoodyear2013_12-0" class="reference"><a href="#cite_note-WillisonGoodyear2013-12"><span>[</span>12<span>]</span></a></sup> Not all antiganglioside antibodies cause disease, and it has recently been suggested that some antibodies bind to more than one type of epitope simultaneously (heterodimeric binding) and that this determines the response. Furthermore, the development of pathogenic antibodies may depend on the presence of ofter strains of bacteria in the bowel.<sup id="cite_ref-WillisonGoodyear2013_12-1" class="reference"><a href="#cite_note-WillisonGoodyear2013-12"><span>[</span>12<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Diagnosis">Diagnosis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=6" title="Edit section: Diagnosis">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>The diagnosis of Guillain–Barré syndrome depends on findings such as rapid development of muscle paralysis, absent reflexes, absence of fever, and a likely cause. Cerebrospinal fluid analysis (through a <a href="/wiki/Lumbar_puncture" title="Lumbar puncture">lumbar spinal puncture</a>) and <a href="/wiki/Nerve_conduction_study" title="Nerve conduction study">nerve conduction studies</a> are supportive investigations commonly performed in the diagnosis of GBS.<sup id="cite_ref-NEJM2012_1-15" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-NatRevNeurol2014_2-14" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup><sup id="cite_ref-Eldar2014_8-1" class="reference"><a href="#cite_note-Eldar2014-8"><span>[</span>8<span>]</span></a></sup> Testing for antiganglioside antibodies is often performed, but their contribution to diagnosis is usually limited.<sup id="cite_ref-NatRevNeurol2014_2-15" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup> Blood tests are generally performed to exclude the possibility of another cause for weakness, such as a <a href="/wiki/Hypokalemia" title="Hypokalemia">low level of potassium in the blood</a>.<sup id="cite_ref-NEJM2012_1-16" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup> An <a href="/wiki/Hyponatremia" title="Hyponatremia">abnormally low level of sodium in the blood</a> is often encountered in Guillain–Barré syndrome. This has been attributed to the <a href="/wiki/Syndrome_of_inappropriate_antidiuretic_hormone_secretion" title="Syndrome of inappropriate antidiuretic hormone secretion">inappropriate secretion of antidiuretic hormone</a>, leading to relative retention of water.<sup id="cite_ref-13" class="reference"><a href="#cite_note-13"><span>[</span>13<span>]</span></a></sup></p>
<p>In many cases, <a href="/wiki/Magnetic_resonance_imaging" title="Magnetic resonance imaging">magnetic resonance imaging</a> of the spinal cord is performed to distinguish between Guillain–Barré syndrome and other conditions causing limb weakness, such as <a href="/wiki/Spinal_cord_compression" title="Spinal cord compression">spinal cord compression</a>.<sup id="cite_ref-NEJM2012_1-17" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-NatRevNeurol2014_2-16" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup> If an MRI scan shows enhancement of the <a href="/wiki/Nerve_root" title="Nerve root">nerve roots</a>, this may be indicative of GBS.<sup id="cite_ref-NatRevNeurol2014_2-17" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup> In children, this feature is present in 95% of scans, but it is not specific to Guillain–Barré syndrome so other confirmation is also needed.<sup id="cite_ref-Ryan2013_3-2" class="reference"><a href="#cite_note-Ryan2013-3"><span>[</span>3<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Spinal_fluid">Spinal fluid</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=7" title="Edit section: Spinal fluid">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Cerebrospinal_fluid" title="Cerebrospinal fluid">Cerebrospinal fluid</a> (CSF) envelops the brain and the spine, and <a href="/wiki/Lumbar_puncture" title="Lumbar puncture">lumbar puncture</a> is the removal of a small amount of fluid using a needle inserted between the <a href="/wiki/Lumbar_vertebrae" title="Lumbar vertebrae">lumbar vertebrae</a>. A characteristic finding in Guillain–Barré syndrome is an elevated protein level with low numbers of <a href="/wiki/White_blood_cell" title="White blood cell">white blood cells</a> ("albuminocytological dissociation"); this distinguishes it from a number of other conditions (such as <a href="/wiki/Lymphoma" title="Lymphoma">lymphoma</a> and <a href="/wiki/Poliomyelitis" title="Poliomyelitis">poliomyelitis</a>) where both the protein and the <a href="/wiki/Pleocytosis" title="Pleocytosis">cell count are elevated</a>. Despite this, the CSF is unremarkable in 50% of people with Guillain–Barré syndrome in the first few days of symptoms, and 80% after the first week; therefore, normal results do not exclude the condition.<sup id="cite_ref-NatRevNeurol2014_2-18" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup></p>
<p>Repeating the lumbar puncture during the disease course is not recommended. The protein levels may rise after treatment has been administered.<sup id="cite_ref-NatRevNeurol2014_2-19" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Neurophysiology">Neurophysiology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=8" title="Edit section: Neurophysiology">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Directly assessing <a href="/wiki/Electrodiagnostic_medicine" title="Electrodiagnostic medicine">nerve conduction of electrical impulses</a> can exclude other causes of acute muscle weakness, as well as distinguish the different types of Guillain–Barré syndrome. Needle <a href="/wiki/Electromyography" title="Electromyography">electromyography</a> (EMG) and <a href="/wiki/Nerve_conduction_study" title="Nerve conduction study">nerve conduction studies</a> may be performed. In the first two weeks these investigations may not show any abnormality.<sup id="cite_ref-NatRevNeurol2014_2-20" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup><sup id="cite_ref-Rinaldi2013_10-1" class="reference"><a href="#cite_note-Rinaldi2013-10"><span>[</span>10<span>]</span></a></sup> Neurophysiology studies are not required for the diagnosis.<sup id="cite_ref-NEJM2012_1-18" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup></p>
<p>Formal criteria exist for each of the main subtypes of Guillain–Barré syndrome (AIDP and AMAN/AMSAN, see below), but these may misclassify some cases (particularly where there is reversible conduction failure) and therefore changes to these criteria have been proposed.<sup id="cite_ref-Uncini2012_14-0" class="reference"><a href="#cite_note-Uncini2012-14"><span>[</span>14<span>]</span></a></sup> Sometimes, repeat testing may be helpful.<sup id="cite_ref-Uncini2012_14-1" class="reference"><a href="#cite_note-Uncini2012-14"><span>[</span>14<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Clinical_subtypes">Clinical subtypes</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=9" title="Edit section: Clinical subtypes">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>A number of subtypes of Guillain–Barré syndrome are recognized.<sup id="cite_ref-NatRevNeurol2014_2-21" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup><sup id="cite_ref-Uncini2012_14-2" class="reference"><a href="#cite_note-Uncini2012-14"><span>[</span>14<span>]</span></a></sup> Despite this, many people have overlapping symptoms that can make the classification difficult in individual cases.<sup id="cite_ref-vanDoorn2008_4-3" class="reference"><a href="#cite_note-vanDoorn2008-4"><span>[</span>4<span>]</span></a></sup><sup id="cite_ref-Wakerley2014_15-0" class="reference"><a href="#cite_note-Wakerley2014-15"><span>[</span>15<span>]</span></a></sup> All types have partial forms. For instance, some people experience only isolated eye movement or coordination problems; these are thought to be a subtype of Miller Fisher syndrome and have similar antiganglioside antibody patterns.<sup id="cite_ref-Shahrizaila2013_5-1" class="reference"><a href="#cite_note-Shahrizaila2013-5"><span>[</span>5<span>]</span></a></sup><sup id="cite_ref-Wakerley2014_15-1" class="reference"><a href="#cite_note-Wakerley2014-15"><span>[</span>15<span>]</span></a></sup></p>
<table class="wikitable" style="margin-left:15px; text-align:center">
<tr>
<th>Type<sup id="cite_ref-NatRevNeurol2014_2-22" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup></th>
<th>Symptoms</th>
<th>Population affected</th>
<th>Nerve conduction studies</th>
<th>Antiganglioside antibodies</th>
</tr>
<tr>
<td>Acute inflammatory demyelinating polyneuropathy (AIDP)</td>
<td>Sensory symptoms and muscle weakness, often with cranial nerve weakness and autonomic involvement</td>
<td>Most common in Europe and North America</td>
<td>Demyelinating polyneuropathy</td>
<td>No clear association</td>
</tr>
<tr>
<td><a href="/wiki/Acute_motor_axonal_neuropathy" title="Acute motor axonal neuropathy">Acute motor axonal neuropathy</a> (AMAN)</td>
<td>Isolated muscle weakness without sensory symptoms in less than 10%; cranial nerve involvement uncommon</td>
<td>Rare in Europe and North America, substantial proportion (30-65%) in Asia and Central and South America; sometimes called "Chinese paralytic syndrome"</td>
<td>Axonal polyneuropathy, normal sensory action potential</td>
<td>GM1a/b, GD1a &amp; GalNac-GD1a</td>
</tr>
<tr>
<td>Acute motor and sensory axonal neuropathy (AMSAN)</td>
<td>Severe muscle weakness similar to AMAN but with sensory loss</td>
<td>-</td>
<td>Axonal polyneuropathy, reduced or absent sensory action potential</td>
<td>GM1, GD1a</td>
</tr>
<tr>
<td>Throat-neck-arm variant</td>
<td>Weakness particularly of the throat muscles, face, neck and shoulder muscles</td>
<td>-</td>
<td>Generally normal, sometimes axonal neuropathy in arms</td>
<td>Mostly GT1a, occasionally GQ1b, rarely GD1a</td>
</tr>
<tr>
<td><a href="/wiki/Miller_Fisher_syndrome" title="Miller Fisher syndrome" class="mw-redirect">Miller Fisher syndrome</a></td>
<td>Ataxia, eye muscle weakness, areflexia but usually no limb weakness</td>
<td>This variant occurs more commonly in men than in women (2:1 ratio). Cases typically occur in the spring and the average age of occurrence is 43 years old.<sup id="cite_ref-Mori2012_16-0" class="reference"><a href="#cite_note-Mori2012-16"><span>[</span>16<span>]</span></a></sup></td>
<td>Generally normal, sometimes discrete changes in sensory conduction or <a href="/wiki/H-reflex" title="H-reflex">H-reflex</a> detected</td>
<td>GQ1b, GT1a</td>
</tr>
</table>
<p>Other diagnostic entities are often included in the spectrum of Guillain–Barré syndrome. <a href="/wiki/Bickerstaff%27s_encephalitis" title="Bickerstaff's encephalitis">Bickerstaff's brainstem encephalitis</a>, for instance, is part of the group of conditions now regarded as forms of Miller Fisher syndrome (anti-GQ1b antibody syndrome),<sup id="cite_ref-Shahrizaila2013_5-2" class="reference"><a href="#cite_note-Shahrizaila2013-5"><span>[</span>5<span>]</span></a></sup> as well as a related condition labelled "acute ataxic hypersomnolence" where coordination problems and drowsiness are present but no muscle weakness can be detected.<sup id="cite_ref-Wakerley2014_15-2" class="reference"><a href="#cite_note-Wakerley2014-15"><span>[</span>15<span>]</span></a></sup> BBE is characterized by the rapid onset of ophthalmoplegia, ataxia, and disturbance of consciousness, and may be associated with absent or decreased tendon reflexes and as well as <a href="/wiki/Plantar_reflex" title="Plantar reflex">Babinski's sign</a>.<sup id="cite_ref-Wakerley2014_15-3" class="reference"><a href="#cite_note-Wakerley2014-15"><span>[</span>15<span>]</span></a></sup> The course of the disease is usually monophasic, but recurrent episodes have been reported. MRI abnormalities in the brainstem have been reported in 11%.<sup id="cite_ref-Shahrizaila2013_5-3" class="reference"><a href="#cite_note-Shahrizaila2013-5"><span>[</span>5<span>]</span></a></sup></p>
<p>Whether isolated acute sensory loss can be regarded as a form of Guillain–Barré syndrome is a matter of dispute; this is a rare occurrence compared to GBS with muscle weakness but no sensory symptoms.<sup id="cite_ref-Rinaldi2013_10-2" class="reference"><a href="#cite_note-Rinaldi2013-10"><span>[</span>10<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Treatment">Treatment</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=10" title="Edit section: Treatment">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Immunotherapy">Immunotherapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=11" title="Edit section: Immunotherapy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Plasmapheresis" title="Plasmapheresis">Plasmapheresis</a> and <a href="/wiki/Intravenous_immunoglobulins" title="Intravenous immunoglobulins" class="mw-redirect">intravenous immunoglobulins</a> (IVIg) are the two main immunotherapy treatments for GBS. Plasmapheresis attempts to reduce the body's attack on the nervous system by filtering antibodies out of the bloodstream. Similarly, administration of IVIg neutralizes harmful antibodies and inflammation. These two treatments are equally effective and a combination of the two is not significantly better than either alone.<sup id="cite_ref-17" class="reference"><a href="#cite_note-17"><span>[</span>17<span>]</span></a></sup> Plasmapheresis speeds recovery when used within four weeks of the onset of symptoms.<sup id="cite_ref-Hughes_18-0" class="reference"><a href="#cite_note-Hughes-18"><span>[</span>18<span>]</span></a></sup> IVIg works as well as plasmapheresis when started within two weeks of the onset of symptoms, and has fewer complications.<sup id="cite_ref-Hughes_18-1" class="reference"><a href="#cite_note-Hughes-18"><span>[</span>18<span>]</span></a></sup> IVIg is usually used first because of its ease of administration and safety. Its use is not without risk; occasionally it causes <a href="/wiki/Hepatitis" title="Hepatitis">liver inflammation</a>, or in rare cases, kidney failure.<sup id="cite_ref-Dantal2013_19-0" class="reference"><a href="#cite_note-Dantal2013-19"><span>[</span>19<span>]</span></a></sup> <a href="/wiki/Glucocorticoids" title="Glucocorticoids" class="mw-redirect">Glucocorticoids</a> alone have not been found to be effective in speeding recovery and could potentially delay recovery.<sup id="cite_ref-20" class="reference"><a href="#cite_note-20"><span>[</span>20<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Pain">Pain</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=12" title="Edit section: Pain">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>While pain is common in people with Guillain–Barré syndrome, studies comparing different types of pain medication are insufficient to make a recommendation as to which should be used.<sup id="cite_ref-21" class="reference"><a href="#cite_note-21"><span>[</span>21<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Rehabilitation">Rehabilitation</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=13" title="Edit section: Rehabilitation">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Following the acute phase, around 40% of people require intensive rehabilitation with the help of a multidisciplinary team to focus on improving <a href="/wiki/Activities_of_daily_living" title="Activities of daily living">activities of daily living</a> (ADLs).<sup id="cite_ref-Khan2012_22-0" class="reference"><a href="#cite_note-Khan2012-22"><span>[</span>22<span>]</span></a></sup> Studies into the subject have been limited, but it is likely that intensive rehabilitation improves long-term symptoms.<sup id="cite_ref-23" class="reference"><a href="#cite_note-23"><span>[</span>23<span>]</span></a></sup> Teams may include <a href="/wiki/Physical_therapy" title="Physical therapy">physical therapists</a>, <a href="/wiki/Occupational_therapy" title="Occupational therapy">occupational therapists</a>, <a href="/wiki/Social_work" title="Social work">social workers</a>, <a href="/wiki/Psychology" title="Psychology">psychologists</a>, other <a href="/wiki/Allied_health_professions" title="Allied health professions">allied health professionals</a> and <a href="/wiki/Nursing" title="Nursing">nurses</a>. The team usually works under the supervision of a neurologist or <a href="/wiki/Physical_medicine_and_rehabilitation" title="Physical medicine and rehabilitation">rehabilitation physician</a> directing treatment goals.<sup id="cite_ref-Khan2012_22-1" class="reference"><a href="#cite_note-Khan2012-22"><span>[</span>22<span>]</span></a></sup></p>
<p>Physiotherapy interventions include strength, endurance and gait training with graduated increases in mobility, maintenance of posture and alignment as well as joint function. Occupational therapy aims to improve everyday function with domestic and community tasks as well as driving and work. Psychologists may provide counseling and support. Home modifications, gait aids, <a href="/wiki/Orthotics" title="Orthotics">orthotics</a> and splints may be provided.<sup id="cite_ref-Khan2012_22-2" class="reference"><a href="#cite_note-Khan2012-22"><span>[</span>22<span>]</span></a></sup> <a href="/wiki/Speech-language_pathology" title="Speech-language pathology">Speech-language pathology</a> input may be required in those with speech and swallowing problems, as well as to support communication in those who require ongoing breathing support (often through a <a href="/wiki/Tracheostomy" title="Tracheostomy" class="mw-redirect">tracheostomy</a>). Nutritional support may be provided by the team and by <a href="/wiki/Dietitian" title="Dietitian">dietitians</a>. Psychological interventions may be required for anxiety, fear and depression.<sup id="cite_ref-Khan2012_22-3" class="reference"><a href="#cite_note-Khan2012-22"><span>[</span>22<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Respiratory_failure_2">Respiratory failure</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=14" title="Edit section: Respiratory failure">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Respiratory failure may require <a href="/wiki/Tracheal_intubation" title="Tracheal intubation">intubation of the windpipe</a> and breathing support through <a href="/wiki/Mechanical_ventilation" title="Mechanical ventilation">mechanical ventilation</a>, generally on an <a href="/wiki/Intensive_care_unit" title="Intensive care unit">intensive care unit</a>. The need for ventilatory support can be anticipated by measurement of two <a href="/wiki/Spirometry" title="Spirometry">spirometry</a>-based breathing tests: the <a href="/wiki/Forced_vital_capacity" title="Forced vital capacity" class="mw-redirect">forced vital capacity</a> (FVC) and the <a href="/wiki/Negative_inspiratory_force" title="Negative inspiratory force" class="mw-redirect">negative inspiratory force</a> (NIF). An FVC of less than 15&#160;ml per kilogram body weight or an NIF of less than 60&#160;<a href="/wiki/Centimetre_of_water" title="Centimetre of water">cmH<sub>2</sub>O</a> are considered markers of severe respiratory failure.<sup id="cite_ref-Dimachkie2013_24-0" class="reference"><a href="#cite_note-Dimachkie2013-24"><span>[</span>24<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Prognosis">Prognosis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=15" title="Edit section: Prognosis">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Guillain–Barré syndrome can lead to death as a result of a number of complications: severe infections, blood clots, and cardiac arrest likely due to autonomic neuropathy. Despite optimum care this occurs in about 5% of cases.<sup id="cite_ref-NEJM2012_1-19" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup></p>
<p>There is a variation in the rate and extent of recovery.<sup id="cite_ref-NEJM2012_1-20" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup> The prognosis of Guillain–Barré syndrome is determined mainly by age (those over 40 may have a poorer outcome), and by the severity of symptoms after two weeks. Furthermore, those who experienced diarrhea before the onset of disease have a worse prognosis.<sup id="cite_ref-vanDoorn2010_6-1" class="reference"><a href="#cite_note-vanDoorn2010-6"><span>[</span>6<span>]</span></a></sup> On the nerve conduction study, the presence of conduction block predicts poorer outcome at 6 months.<sup id="cite_ref-vanDoorn2010_6-2" class="reference"><a href="#cite_note-vanDoorn2010-6"><span>[</span>6<span>]</span></a></sup> In those who have received intravenous immunoglobulins, a smaller increase in IgG in the blood two weeks after administration is associated with poorer mobility outcomes at six months than those whose IgG level increased substantially.<sup id="cite_ref-vanDoorn2010_6-3" class="reference"><a href="#cite_note-vanDoorn2010-6"><span>[</span>6<span>]</span></a></sup> If the disease continues to progress beyond four weeks, or there are multiple fluctuations in the severity (more than two in eight weeks), the diagnosis may be <a href="/wiki/Chronic_inflammatory_demyelinating_polyneuropathy" title="Chronic inflammatory demyelinating polyneuropathy">chronic inflammatory demyelinating polyneuropathy</a> which is treated differently.<sup id="cite_ref-NatRevNeurol2014_2-23" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup></p>
<p>In research studies, the outcome from an episode of Guillain–Barré syndrome is recorded on a scale from 0-6, where 0 denotes completely healthy, 1 very minor symptoms but able to run, 2 able to walk but not to run, 3 requiring a stick or other support, 4 confined to bed or chair, 5 requiring long-term respiratory support, 6 death.<sup id="cite_ref-25" class="reference"><a href="#cite_note-25"><span>[</span>25<span>]</span></a></sup></p>
<p>The <a href="/wiki/Quality_of_life_(healthcare)" title="Quality of life (healthcare)">health-related quality of life</a> (HRQL) after an attack of Guillain–Barré syndrome can be significantly impaired. About a fifth are unable to walk unaided after six months, and many experience <a href="/wiki/Chronic_pain" title="Chronic pain">chronic pain</a>, <a href="/wiki/Fatigue_(medical)" title="Fatigue (medical)">fatigue</a> and difficulty with work, education, hobbies and social activities.<sup id="cite_ref-Darweesh2014_26-0" class="reference"><a href="#cite_note-Darweesh2014-26"><span>[</span>26<span>]</span></a></sup> HRQL improves significantly in the first year.<sup id="cite_ref-Darweesh2014_26-1" class="reference"><a href="#cite_note-Darweesh2014-26"><span>[</span>26<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Epidemiology">Epidemiology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=16" title="Edit section: Epidemiology">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>In Western countries, the number of new episodes per year has been estimated to be between 0.89 and 1.89 cases per 100,000 people. Children and young adults are less likely to be affected than the elderly: the risk increases by 20% for every decade of life.<sup id="cite_ref-Sejvar2011_27-0" class="reference"><a href="#cite_note-Sejvar2011-27"><span>[</span>27<span>]</span></a></sup> Men are more likely to develop Guillain–Barré syndrome than women; the <a href="/wiki/Relative_risk" title="Relative risk">relative risk</a> for men is 1.78 compared to women.<sup id="cite_ref-NEJM2012_1-21" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-Sejvar2011_27-1" class="reference"><a href="#cite_note-Sejvar2011-27"><span>[</span>27<span>]</span></a></sup></p>
<p>The distribution of subtypes varies between countries. In Europe and the United States, 60–80% of people with Guillain–Barré syndrome have the demyelinating subtype (AIDP), and AMAN affects only a small number (6–7%). In Asia and Central and South America, that proportion is significantly higher (30–65%). This may be related to the exposure to different kinds of infection, but also the genetic characteristics of that population.<sup id="cite_ref-NatRevNeurol2014_2-24" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup> Miller Fisher variant is thought to be more common in Southeast Asia.<sup id="cite_ref-NEJM2012_1-22" class="reference"><a href="#cite_note-NEJM2012-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-Shahrizaila2013_5-4" class="reference"><a href="#cite_note-Shahrizaila2013-5"><span>[</span>5<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="History">History</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=17" title="Edit section: History">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Georges_Guillain.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/5/5f/Georges_Guillain.jpg/220px-Georges_Guillain.jpg" width="220" height="331" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/5/5f/Georges_Guillain.jpg/330px-Georges_Guillain.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/5/5f/Georges_Guillain.jpg/440px-Georges_Guillain.jpg 2x" data-file-width="524" data-file-height="788" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Georges_Guillain.jpg" class="internal" title="Enlarge"></a></div>
Georges Guillain, together with Barré and Strohl, described two cases of self-limiting acute paralysis with peculiar changes in the cerebrospinal fluid. He succeeded his teacher <a href="/wiki/Pierre_Marie" title="Pierre Marie">Pierre Marie</a> as professor of neurology at the <a href="/wiki/Piti%C3%A9-Salp%C3%AAtri%C3%A8re_Hospital" title="Pitié-Salpêtrière Hospital">Salpêtrière</a> hospital in Paris in 1925.<sup id="cite_ref-28" class="reference"><a href="#cite_note-28"><span>[</span>28<span>]</span></a></sup></div>
</div>
</div>
<p>French physician <a href="/wiki/Jean_Landry_(physician)" title="Jean Landry (physician)">Jean-Baptiste Octave Landry</a> first described the disorder in 1859.<sup id="cite_ref-29" class="reference"><a href="#cite_note-29"><span>[</span>29<span>]</span></a></sup> In 1916, <a href="/wiki/Georges_Guillain" title="Georges Guillain">Georges Guillain</a>, <a href="/wiki/Jean_Alexandre_Barr%C3%A9" title="Jean Alexandre Barré">Jean Alexandre Barré</a>, and <a href="/wiki/Andr%C3%A9_Strohl" title="André Strohl">André Strohl</a> diagnosed two soldiers with the illness and described the key diagnostic abnormality—albuminocytological dissociation—of increased spinal fluid protein concentration but a normal cell count.<sup id="cite_ref-vanDoorn2008_4-4" class="reference"><a href="#cite_note-vanDoorn2008-4"><span>[</span>4<span>]</span></a></sup><sup id="cite_ref-Eldar2014_8-2" class="reference"><a href="#cite_note-Eldar2014-8"><span>[</span>8<span>]</span></a></sup><sup id="cite_ref-Guillain1916_30-0" class="reference"><a href="#cite_note-Guillain1916-30"><span>[</span>30<span>]</span></a></sup></p>
<p>Canadian neurologist <a href="/wiki/Miller_Fisher" title="Miller Fisher" class="mw-redirect">C. Miller Fisher</a> described the variant that bears his name in 1956.<sup id="cite_ref-Shahrizaila2013_5-5" class="reference"><a href="#cite_note-Shahrizaila2013-5"><span>[</span>5<span>]</span></a></sup><sup id="cite_ref-31" class="reference"><a href="#cite_note-31"><span>[</span>31<span>]</span></a></sup> British neurologist <a href="/wiki/Edwin_Bickerstaff" title="Edwin Bickerstaff">Edwin Bickerstaff</a>, based in Birmingham, described the brainstem encephalitis type in 1951 with Philip Cloake, and made further contributions with another paper in 1957.<sup id="cite_ref-Shahrizaila2013_5-6" class="reference"><a href="#cite_note-Shahrizaila2013-5"><span>[</span>5<span>]</span></a></sup><sup id="cite_ref-32" class="reference"><a href="#cite_note-32"><span>[</span>32<span>]</span></a></sup><sup id="cite_ref-33" class="reference"><a href="#cite_note-33"><span>[</span>33<span>]</span></a></sup> Guillain had reported on some of these features prior to their full description in 1938.<sup id="cite_ref-Shahrizaila2013_5-7" class="reference"><a href="#cite_note-Shahrizaila2013-5"><span>[</span>5<span>]</span></a></sup> Further subtypes have been described since then, such as the form featuring pure ataxia and the type causing pharyngeal-cervical-brachial weakness.<sup id="cite_ref-Shahrizaila2013_5-8" class="reference"><a href="#cite_note-Shahrizaila2013-5"><span>[</span>5<span>]</span></a></sup> The axonal subtype was first described in the 1990s.<sup id="cite_ref-Kuwabara2013_11-1" class="reference"><a href="#cite_note-Kuwabara2013-11"><span>[</span>11<span>]</span></a></sup></p>
<p>Diagnostic criteria were developed in the late 1970s after the series of cases associated with swine flu vaccination. These were refined in 1990.<sup id="cite_ref-NatRevNeurol2014_2-25" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup><sup id="cite_ref-34" class="reference"><a href="#cite_note-34"><span>[</span>34<span>]</span></a></sup> The case definition was revised by the <a href="/wiki/Brighton_Collaboration" title="Brighton Collaboration">Brighton Collaboration</a> for vaccine safety in 2009,<sup id="cite_ref-35" class="reference"><a href="#cite_note-35"><span>[</span>35<span>]</span></a></sup> but is mainly intended for research.<sup id="cite_ref-NatRevNeurol2014_2-26" class="reference"><a href="#cite_note-NatRevNeurol2014-2"><span>[</span>2<span>]</span></a></sup> Plasma exchange was first used in 1978 and its benefit confirmed in larger studies in 1985.<sup id="cite_ref-Walgaard2011_36-0" class="reference"><a href="#cite_note-Walgaard2011-36"><span>[</span>36<span>]</span></a></sup> Intravenous immunoglobulins were introduced in 1988, and its non-inferiority compared to plasma exchange was demonstrated in studies in the early 1990s.<sup id="cite_ref-Walgaard2011_36-1" class="reference"><a href="#cite_note-Walgaard2011-36"><span>[</span>36<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Research_directions">Research directions</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=18" title="Edit section: Research directions">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>The understanding of the disease mechanism of Guillain–Barré syndrome has evolved in recent years.<sup id="cite_ref-Rinaldi2013_10-3" class="reference"><a href="#cite_note-Rinaldi2013-10"><span>[</span>10<span>]</span></a></sup> Development of new treatments has been limited since immunotherapy was introduced in the 1980s and 1990s.<sup id="cite_ref-Rinaldi2013_10-4" class="reference"><a href="#cite_note-Rinaldi2013-10"><span>[</span>10<span>]</span></a></sup><sup id="cite_ref-Walgaard2011_36-2" class="reference"><a href="#cite_note-Walgaard2011-36"><span>[</span>36<span>]</span></a></sup> Current research is aimed at demonstrating whether some people who have received IVIg might benefit from a second course if the antibody levels measured in blood after treatment have only shown a small increase.<sup id="cite_ref-vanDoorn2010_6-4" class="reference"><a href="#cite_note-vanDoorn2010-6"><span>[</span>6<span>]</span></a></sup><sup id="cite_ref-Walgaard2011_36-3" class="reference"><a href="#cite_note-Walgaard2011-36"><span>[</span>36<span>]</span></a></sup> Studies of the immunosuppressive drug <a href="/wiki/Mycophenolic_acid" title="Mycophenolic acid">mycophenolate mofetil</a>, <a href="/wiki/Brain-derived_neurotrophic_factor" title="Brain-derived neurotrophic factor">brain-derived neurotrophic factor</a> and <a href="/wiki/Interferon_type_I" title="Interferon type I">Interferon beta</a> (IFN-β) have not demonstrated benefit to support their widespread use.<sup id="cite_ref-Walgaard2011_36-4" class="reference"><a href="#cite_note-Walgaard2011-36"><span>[</span>36<span>]</span></a></sup></p>
<p>An animal model (experimental autoimmune neuritis in rats) is often used for studies, and some agents have shown promise: <a href="/wiki/Glatiramer_acetate" title="Glatiramer acetate">glatiramer acetate</a>, <a href="/w/index.php?title=Quinpramine&amp;action=edit&amp;redlink=1" class="new" title="Quinpramine (page does not exist)">quinpramine</a>, <a href="/w/index.php?title=Fausadil&amp;action=edit&amp;redlink=1" class="new" title="Fausadil (page does not exist)">fausadil</a> (an inhibitor of the <a href="/wiki/Rho-associated_protein_kinase" title="Rho-associated protein kinase">Rho-kinase</a> enzyme),<sup id="cite_ref-Rinaldi2013_10-5" class="reference"><a href="#cite_note-Rinaldi2013-10"><span>[</span>10<span>]</span></a></sup> and the heart drug <a href="/wiki/Flecainide" title="Flecainide">flecainide</a>.<sup id="cite_ref-Walgaard2011_36-5" class="reference"><a href="#cite_note-Walgaard2011-36"><span>[</span>36<span>]</span></a></sup> An antibody targeted against the anti-GD3 antiganglioside antibody has shown benefit in laboratory research.<sup id="cite_ref-Rinaldi2013_10-6" class="reference"><a href="#cite_note-Rinaldi2013-10"><span>[</span>10<span>]</span></a></sup> Given the role of the complement system in GBS, it has been suggested that complement inhibitors (such as the drug <a href="/wiki/Eculizumab" title="Eculizumab">eculizumab</a>) may be effective.<sup id="cite_ref-Walgaard2011_36-6" class="reference"><a href="#cite_note-Walgaard2011-36"><span>[</span>36<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="See_also">See also</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=19" title="Edit section: See also">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><a href="/wiki/List_of_people_with_Guillain%E2%80%93Barr%C3%A9_syndrome" title="List of people with Guillain–Barré syndrome">List of people with Guillain–Barré syndrome</a></li>
</ul>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=20" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist columns references-column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;">
<ol class="references">
<li id="cite_note-NEJM2012-1"><span class="mw-cite-backlink">^ <a href="#cite_ref-NEJM2012_1-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-19"><sup><i><b>t</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-20"><sup><i><b>u</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-21"><sup><i><b>v</b></i></sup></a> <a href="#cite_ref-NEJM2012_1-22"><sup><i><b>w</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Yuki, Nobuhiro; Hartung, Hans-Peter (14 June 2012). "Guillain–Barré Syndrome". <i>New England Journal of Medicine</i> <b>366</b> (24): 2294–2304. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJMra1114525">10.1056/NEJMra1114525</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22694000">22694000</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Guillain%E2%80%93Barr%C3%A9+Syndrome&amp;rft.aufirst=Nobuhiro&amp;rft.au=Hartung%2C+Hans-Peter&amp;rft.aulast=Yuki&amp;rft.au=Yuki%2C+Nobuhiro&amp;rft.date=14+June+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMra1114525&amp;rft_id=info%3Apmid%2F22694000&amp;rft.issue=24&amp;rft.jtitle=New+England+Journal+of+Medicine&amp;rft.pages=2294-2304&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=366" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-NatRevNeurol2014-2"><span class="mw-cite-backlink">^ <a href="#cite_ref-NatRevNeurol2014_2-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-19"><sup><i><b>t</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-20"><sup><i><b>u</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-21"><sup><i><b>v</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-22"><sup><i><b>w</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-23"><sup><i><b>x</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-24"><sup><i><b>y</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-25"><sup><i><b>z</b></i></sup></a> <a href="#cite_ref-NatRevNeurol2014_2-26"><sup><i><b>aa</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">van den Berg, Bianca; Walgaard, Christa; Drenthen, Judith; Fokke, Christiaan; Jacobs, Bart C.; van Doorn, Pieter A. (15 July 2014). "Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis". <i>Nature Reviews Neurology</i> <b>10</b> (8): 469–482. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fnrneurol.2014.121">10.1038/nrneurol.2014.121</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25023340">25023340</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Guillain%E2%80%93Barr%C3%A9+syndrome%3A+pathogenesis%2C+diagnosis%2C+treatment+and+prognosis&amp;rft.au=Drenthen%2C+Judith&amp;rft.aufirst=Bianca&amp;rft.au=Fokke%2C+Christiaan&amp;rft.au=Jacobs%2C+Bart+C.&amp;rft.aulast=van+den+Berg&amp;rft.au=van+den+Berg%2C+Bianca&amp;rft.au=van+Doorn%2C+Pieter+A.&amp;rft.au=Walgaard%2C+Christa&amp;rft.date=15+July+2014&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fnrneurol.2014.121&amp;rft_id=info%3Apmid%2F25023340&amp;rft.issue=8&amp;rft.jtitle=Nature+Reviews+Neurology&amp;rft.pages=469-482&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=10" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Ryan2013-3"><span class="mw-cite-backlink">^ <a href="#cite_ref-Ryan2013_3-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Ryan2013_3-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Ryan2013_3-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Ryan, Monique M. (December 2013). "Pediatric Guillain-Barré syndrome". <i>Current Opinion in Pediatrics</i> <b>25</b> (6): 689–693. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1097%2FMOP.0b013e328365ad3f">10.1097/MOP.0b013e328365ad3f</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24240288">24240288</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Pediatric+Guillain-Barr%C3%A9+syndrome&amp;rft.aufirst=Monique+M.&amp;rft.aulast=Ryan&amp;rft.au=Ryan%2C+Monique+M.&amp;rft.date=December+2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1097%2FMOP.0b013e328365ad3f&amp;rft_id=info%3Apmid%2F24240288&amp;rft.issue=6&amp;rft.jtitle=Current+Opinion+in+Pediatrics&amp;rft.pages=689-693&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=25" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-vanDoorn2008-4"><span class="mw-cite-backlink">^ <a href="#cite_ref-vanDoorn2008_4-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-vanDoorn2008_4-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-vanDoorn2008_4-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-vanDoorn2008_4-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-vanDoorn2008_4-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">van Doorn, Pieter A; Ruts, Liselotte; Jacobs, Bart C (October 2008). "Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome". <i>The Lancet Neurology</i> <b>7</b> (10): 939–950. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS1474-4422%2808%2970215-1">10.1016/S1474-4422(08)70215-1</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18848313">18848313</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Clinical+features%2C+pathogenesis%2C+and+treatment+of+Guillain-Barr%C3%A9+syndrome&amp;rft.aufirst=Pieter+A&amp;rft.au=Jacobs%2C+Bart+C&amp;rft.aulast=van+Doorn&amp;rft.au=Ruts%2C+Liselotte&amp;rft.au=van+Doorn%2C+Pieter+A&amp;rft.date=October+2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS1474-4422%2808%2970215-1&amp;rft_id=info%3Apmid%2F18848313&amp;rft.issue=10&amp;rft.jtitle=The+Lancet+Neurology&amp;rft.pages=939-950&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=7" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Shahrizaila2013-5"><span class="mw-cite-backlink">^ <a href="#cite_ref-Shahrizaila2013_5-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Shahrizaila2013_5-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Shahrizaila2013_5-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Shahrizaila2013_5-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Shahrizaila2013_5-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Shahrizaila2013_5-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Shahrizaila2013_5-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Shahrizaila2013_5-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Shahrizaila2013_5-8"><sup><i><b>i</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Shahrizaila, N.; Yuki, N. (15 September 2012). "Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome". <i>Journal of Neurology, Neurosurgery &amp; Psychiatry</i> <b>84</b> (5): 576–583. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1136%2Fjnnp-2012-302824">10.1136/jnnp-2012-302824</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22984203">22984203</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Bickerstaff+brainstem+encephalitis+and+Fisher+syndrome%3A+anti-GQ1b+antibody+syndrome&amp;rft.aufirst=N.&amp;rft.aulast=Shahrizaila&amp;rft.au=Shahrizaila%2C+N.&amp;rft.au=Yuki%2C+N.&amp;rft.date=15+September+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1136%2Fjnnp-2012-302824&amp;rft_id=info%3Apmid%2F22984203&amp;rft.issue=5&amp;rft.jtitle=Journal+of+Neurology%2C+Neurosurgery+%26+Psychiatry&amp;rft.pages=576-583&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=84" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-vanDoorn2010-6"><span class="mw-cite-backlink">^ <a href="#cite_ref-vanDoorn2010_6-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-vanDoorn2010_6-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-vanDoorn2010_6-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-vanDoorn2010_6-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-vanDoorn2010_6-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">van Doorn PA, Kuitwaard K, Walgaard C et al. (May 2010). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2883091">"IVIG treatment and prognosis in Guillain-Barré syndrome"</a>. <i>Journal of Clinical Immunology</i>. 30 Suppl 1: S74–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1007%2Fs10875-010-9407-4">10.1007/s10875-010-9407-4</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2883091">2883091</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20396937">20396937</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=IVIG+treatment+and+prognosis+in+Guillain-Barr%C3%A9+syndrome&amp;rft.aulast=van+Doorn+PA%2C+Kuitwaard+K%2C+Walgaard+C&amp;rft.au=van+Doorn+PA%2C+Kuitwaard+K%2C+Walgaard+C&amp;rft.date=May+2010&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2883091&amp;rft_id=info%3Adoi%2F10.1007%2Fs10875-010-9407-4&amp;rft_id=info%3Apmc%2F2883091&amp;rft_id=info%3Apmid%2F20396937&amp;rft.jtitle=Journal+of+Clinical+Immunology&amp;rft.pages=S74-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=30+Suppl+1" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-Carod2013-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-Carod2013_7-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Carod-Artal FJ, Wichmann O, Farrar J, Gascón J (September 2013). "Neurological complications of dengue virus infection". <i>The Lancet Neurology</i> <b>12</b> (9): 906–19. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS1474-4422%2813%2970150-9">10.1016/S1474-4422(13)70150-9</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23948177">23948177</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Neurological+complications+of+dengue+virus+infection&amp;rft.au=Carod-Artal+FJ%2C+Wichmann+O%2C+Farrar+J%2C+Gasc%C3%B3n+J&amp;rft.aulast=Carod-Artal+FJ%2C+Wichmann+O%2C+Farrar+J%2C+Gasc%C3%B3n+J&amp;rft.date=September+2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS1474-4422%2813%2970150-9&amp;rft_id=info%3Apmid%2F23948177&amp;rft.issue=9&amp;rft.jtitle=The+Lancet+Neurology&amp;rft.pages=906-19&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=12" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Eldar2014-8"><span class="mw-cite-backlink">^ <a href="#cite_ref-Eldar2014_8-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Eldar2014_8-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Eldar2014_8-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Eldar AH, Chapman J (April 2014). "Guillain Barré syndrome and other immune mediated neuropathies: diagnosis and classification". <i>Autoimmunity Reviews</i> <b>13</b> (4-5): 525–30. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.autrev.2014.01.033">10.1016/j.autrev.2014.01.033</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24434363">24434363</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Guillain+Barr%C3%A9+syndrome+and+other+immune+mediated+neuropathies%3A+diagnosis+and+classification&amp;rft.au=Eldar+AH%2C+Chapman+J&amp;rft.aulast=Eldar+AH%2C+Chapman+J&amp;rft.date=April+2014&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.autrev.2014.01.033&amp;rft_id=info%3Apmid%2F24434363&amp;rft.issue=4-5&amp;rft.jtitle=Autoimmunity+Reviews&amp;rft.pages=525-30&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=13" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Lehmann2010-9"><span class="mw-cite-backlink"><b><a href="#cite_ref-Lehmann2010_9-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Lehmann HC, Hartung HP, Kieseier BC, Hughes RA (Sep 2010). "Guillain-Barré syndrome following influenza vaccination". <i>The Lancet Infectious Diseases</i> <b>10</b> (9): 643–51. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS1473-3099%2810%2970140-7">10.1016/S1473-3099(10)70140-7</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20797646">20797646</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Guillain-Barr%C3%A9+syndrome+following+influenza+vaccination&amp;rft.aulast=Lehmann+HC%2C+Hartung+HP%2C+Kieseier+BC%2C+Hughes+RA&amp;rft.au=Lehmann+HC%2C+Hartung+HP%2C+Kieseier+BC%2C+Hughes+RA&amp;rft.date=Sep+2010&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS1473-3099%2810%2970140-7&amp;rft_id=info%3Apmid%2F20797646&amp;rft.issue=9&amp;rft.jtitle=The+Lancet+Infectious+Diseases&amp;rft.pages=643-51&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=10" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Rinaldi2013-10"><span class="mw-cite-backlink">^ <a href="#cite_ref-Rinaldi2013_10-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Rinaldi2013_10-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Rinaldi2013_10-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Rinaldi2013_10-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Rinaldi2013_10-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Rinaldi2013_10-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Rinaldi2013_10-6"><sup><i><b>g</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Rinaldi, Simon (June 2013). "Update on Guillain-Barré syndrome". <i>Journal of the Peripheral Nervous System</i> <b>18</b> (2): 99–112. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fjns5.12020">10.1111/jns5.12020</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23781958">23781958</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Update+on+Guillain-Barr%C3%A9+syndrome&amp;rft.aufirst=Simon&amp;rft.aulast=Rinaldi&amp;rft.au=Rinaldi%2C+Simon&amp;rft.date=June+2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fjns5.12020&amp;rft_id=info%3Apmid%2F23781958&amp;rft.issue=2&amp;rft.jtitle=Journal+of+the+Peripheral+Nervous+System&amp;rft.pages=99-112&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=18" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Kuwabara2013-11"><span class="mw-cite-backlink">^ <a href="#cite_ref-Kuwabara2013_11-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Kuwabara2013_11-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Kuwabara S, Yuki N (December 2013). "Axonal Guillain-Barré syndrome: concepts and controversies". <i>The Lancet Neurology</i> <b>12</b> (12): 1180–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS1474-4422%2813%2970215-1">10.1016/S1474-4422(13)70215-1</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24229616">24229616</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Axonal+Guillain-Barr%C3%A9+syndrome%3A+concepts+and+controversies&amp;rft.au=Kuwabara+S%2C+Yuki+N&amp;rft.aulast=Kuwabara+S%2C+Yuki+N&amp;rft.date=December+2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS1474-4422%2813%2970215-1&amp;rft_id=info%3Apmid%2F24229616&amp;rft.issue=12&amp;rft.jtitle=The+Lancet+Neurology&amp;rft.pages=1180-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=12" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-WillisonGoodyear2013-12"><span class="mw-cite-backlink">^ <a href="#cite_ref-WillisonGoodyear2013_12-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-WillisonGoodyear2013_12-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Willison, Hugh J.; Goodyear, Carl S. (September 2013). "Glycolipid antigens and autoantibodies in autoimmune neuropathies". <i>Trends in Immunology</i> <b>34</b> (9): 453–459. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.it.2013.05.001">10.1016/j.it.2013.05.001</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23770405">23770405</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Glycolipid+antigens+and+autoantibodies+in+autoimmune+neuropathies&amp;rft.aufirst=Hugh+J.&amp;rft.au=Goodyear%2C+Carl+S.&amp;rft.aulast=Willison&amp;rft.au=Willison%2C+Hugh+J.&amp;rft.date=September+2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.it.2013.05.001&amp;rft_id=info%3Apmid%2F23770405&amp;rft.issue=9&amp;rft.jtitle=Trends+in+Immunology&amp;rft.pages=453-459&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=34" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-13">^</a></b></span> <span class="reference-text"><span class="citation journal">Spasovski G, Vanholder R, Allolio B et al. (25 Feb 2014). <a rel="nofollow" class="external text" href="http://www.eje-online.org/content/170/3/G1.full">"Clinical practice guideline on diagnosis and treatment of hyponatraemia"</a>. <i>European Journal of Endocrinology</i> <b>170</b> (3): G1–47. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1530%2FEJE-13-1020">10.1530/EJE-13-1020</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Clinical+practice+guideline+on+diagnosis+and+treatment+of+hyponatraemia&amp;rft.aulast=Spasovski+G%2C+Vanholder+R%2C+Allolio+B&amp;rft.au=Spasovski+G%2C+Vanholder+R%2C+Allolio+B&amp;rft.date=25+Feb+2014&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.eje-online.org%2Fcontent%2F170%2F3%2FG1.full&amp;rft_id=info%3Adoi%2F10.1530%2FEJE-13-1020&amp;rft.issue=3&amp;rft.jtitle=European+Journal+of+Endocrinology&amp;rft.pages=G1-47&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=170" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-Uncini2012-14"><span class="mw-cite-backlink">^ <a href="#cite_ref-Uncini2012_14-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Uncini2012_14-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Uncini2012_14-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Uncini A, Kuwabara S (August 2012). "Electrodiagnostic criteria for Guillain-Barrè syndrome: a critical revision and the need for an update". <i>Clinical Neurophysiology</i> <b>123</b> (8): 1487–95. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.clinph.2012.01.025">10.1016/j.clinph.2012.01.025</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22480600">22480600</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Electrodiagnostic+criteria+for+Guillain-Barr%C3%A8+syndrome%3A+a+critical+revision+and+the+need+for+an+update&amp;rft.aulast=Uncini+A%2C+Kuwabara+S&amp;rft.au=Uncini+A%2C+Kuwabara+S&amp;rft.date=August+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.clinph.2012.01.025&amp;rft_id=info%3Apmid%2F22480600&amp;rft.issue=8&amp;rft.jtitle=Clinical+Neurophysiology&amp;rft.pages=1487-95&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=123" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Wakerley2014-15"><span class="mw-cite-backlink">^ <a href="#cite_ref-Wakerley2014_15-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Wakerley2014_15-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Wakerley2014_15-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Wakerley2014_15-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Wakerley BR, Uncini A, Yuki N; GBS Classification Group (September 2014). "Guillain-Barré and Miller Fisher syndromes--new diagnostic classification". <i>Nature Reviews Neurology.</i> <b>10</b> (9): 537–44. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fnrneurol.2014.138">10.1038/nrneurol.2014.138</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25072194">25072194</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Guillain-Barr%C3%A9+and+Miller+Fisher+syndromes--new+diagnostic+classification&amp;rft.aulast=Wakerley+BR%2C+Uncini+A%2C+Yuki+N%3B+GBS+Classification+Group&amp;rft.au=Wakerley+BR%2C+Uncini+A%2C+Yuki+N%3B+GBS+Classification+Group&amp;rft.date=September+2014&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fnrneurol.2014.138&amp;rft_id=info%3Apmid%2F25072194&amp;rft.issue=9&amp;rft.jtitle=Nature+Reviews+Neurology.&amp;rft.pages=537-44&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=10" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Mori2012-16"><span class="mw-cite-backlink"><b><a href="#cite_ref-Mori2012_16-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Mori M, Kuwabara S, Yuki N (January 2012). "Fisher syndrome: clinical features, immunopathogenesis and management". <i>Expert Rev Neurother</i> <b>12</b> (1): 39–51. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1586%2Fern.11.182">10.1586/ern.11.182</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22149656">22149656</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Fisher+syndrome%3A+clinical+features%2C+immunopathogenesis+and+management&amp;rft.aulast=Mori+M%2C+Kuwabara+S%2C+Yuki+N&amp;rft.au=Mori+M%2C+Kuwabara+S%2C+Yuki+N&amp;rft.date=January+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1586%2Fern.11.182&amp;rft_id=info%3Apmid%2F22149656&amp;rft.issue=1&amp;rft.jtitle=Expert+Rev+Neurother&amp;rft.pages=39-51&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=12" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-17">^</a></b></span> <span class="reference-text"><span class="citation journal">Hughes, RA; Swan, AV; van Doorn, PA (Sep 19, 2014). "Intravenous immunoglobulin for Guillain-Barré syndrome.". <i>The Cochrane Database of Systematic Reviews</i> <b>9</b>: CD002063. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2F14651858.CD002063.pub6">10.1002/14651858.CD002063.pub6</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25238327">25238327</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Intravenous+immunoglobulin+for+Guillain-Barr%C3%A9+syndrome.&amp;rft.aufirst=RA&amp;rft.au=Hughes%2C+RA&amp;rft.aulast=Hughes&amp;rft.au=Swan%2C+AV&amp;rft.au=van+Doorn%2C+PA&amp;rft.date=Sep+19%2C+2014&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD002063.pub6&amp;rft_id=info%3Apmid%2F25238327&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.pages=CD002063&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=9" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Hughes-18"><span class="mw-cite-backlink">^ <a href="#cite_ref-Hughes_18-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Hughes_18-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC (September 2003). <a rel="nofollow" class="external text" href="http://www.neurology.org/content/61/6/736.full.html">"Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology"</a>. <i>Neurology</i> <b>61</b> (6): 736–40. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1212%2FWNL.61.6.736">10.1212/WNL.61.6.736</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14504313">14504313</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Practice+parameter%3A+immunotherapy+for+Guillain-Barr%C3%A9+syndrome%3A+report+of+the+Quality+Standards+Subcommittee+of+the+American+Academy+of+Neurology&amp;rft.au=Hughes+RA%2C+Wijdicks+EF%2C+Barohn+R%2C+Benson+E%2C+Cornblath+DR%2C+Hahn+AF%2C+Meythaler+JM%2C+Miller+RG%2C+Sladky+JT%2C+Stevens+JC&amp;rft.aulast=Hughes+RA%2C+Wijdicks+EF%2C+Barohn+R%2C+Benson+E%2C+Cornblath+DR%2C+Hahn+AF%2C+Meythaler+JM%2C+Miller+RG%2C+Sladky+JT%2C+Stevens+JC&amp;rft.date=September+2003&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.neurology.org%2Fcontent%2F61%2F6%2F736.full.html&amp;rft_id=info%3Adoi%2F10.1212%2FWNL.61.6.736&amp;rft_id=info%3Apmid%2F14504313&amp;rft.issue=6&amp;rft.jtitle=Neurology&amp;rft.pages=736-40&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=61" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Dantal2013-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-Dantal2013_19-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Dantal J (October 2013). <a rel="nofollow" class="external text" href="http://www.karger.com/Article/FullText/354893">"Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk"</a>. <i>American Journal of Nephrology</i> <b>38</b> (4): 275–84. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1159%2F000354893">10.1159/000354893</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24051350">24051350</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Intravenous+immunoglobulins%3A+in-depth+review+of+excipients+and+acute+kidney+injury+risk&amp;rft.au=Dantal+J&amp;rft.aulast=Dantal+J&amp;rft.date=October+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.karger.com%2FArticle%2FFullText%2F354893&amp;rft_id=info%3Adoi%2F10.1159%2F000354893&amp;rft_id=info%3Apmid%2F24051350&amp;rft.issue=4&amp;rft.jtitle=American+Journal+of+Nephrology&amp;rft.pages=275-84&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=38" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-20">^</a></b></span> <span class="reference-text"><span class="citation journal">Hughes, RA; van Doorn, PA (15 August 2012). "Corticosteroids for Guillain-Barré syndrome.". <i>The Cochrane Database of Systematic Reviews</i> <b>8</b>: CD001446. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2F14651858.CD001446.pub4">10.1002/14651858.CD001446.pub4</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22895921">22895921</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Corticosteroids+for+Guillain-Barr%C3%A9+syndrome.&amp;rft.aufirst=RA&amp;rft.au=Hughes%2C+RA&amp;rft.aulast=Hughes&amp;rft.au=van+Doorn%2C+PA&amp;rft.date=15+August+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD001446.pub4&amp;rft_id=info%3Apmid%2F22895921&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.pages=CD001446&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=8" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text"><span class="citation journal">Liu, J; Wang, LN; McNicol, ED (20 October 2013). "Pharmacological treatment for pain in Guillain-Barré syndrome.". <i>The Cochrane Database of Systematic Reviews</i> <b>10</b>: CD009950. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2F14651858.CD009950.pub2">10.1002/14651858.CD009950.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24142399">24142399</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Pharmacological+treatment+for+pain+in+Guillain-Barr%C3%A9+syndrome.&amp;rft.aufirst=J&amp;rft.aulast=Liu&amp;rft.au=Liu%2C+J&amp;rft.au=McNicol%2C+ED&amp;rft.au=Wang%2C+LN&amp;rft.date=20+October+2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD009950.pub2&amp;rft_id=info%3Apmid%2F24142399&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.pages=CD009950&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=10" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Khan2012-22"><span class="mw-cite-backlink">^ <a href="#cite_ref-Khan2012_22-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Khan2012_22-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Khan2012_22-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Khan2012_22-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Khan, F.; Amatya, B. (September 2012). <a rel="nofollow" class="external text" href="http://www.minervamedica.it/en/journals/europa-medicophysica/article.php?cod=R33Y2012N03A0507">"Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review."</a>. <i>European journal of physical and rehabilitation medicine</i> <b>48</b> (3): 507–22. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22820829">22820829</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Rehabilitation+interventions+in+patients+with+acute+demyelinating+inflammatory+polyneuropathy%3A+a+systematic+review.&amp;rft.au=Amatya%2C+B.&amp;rft.aufirst=F.&amp;rft.au=Khan%2C+F.&amp;rft.aulast=Khan&amp;rft.date=September+2012&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.minervamedica.it%2Fen%2Fjournals%2Feuropa-medicophysica%2Farticle.php%3Fcod%3DR33Y2012N03A0507&amp;rft_id=info%3Apmid%2F22820829&amp;rft.issue=3&amp;rft.jtitle=European+journal+of+physical+and+rehabilitation+medicine&amp;rft.pages=507-22&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=48" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text"><span class="citation journal">Khan, F; Ng, L; Amatya, B; Brand, C; Turner-Stokes, L (6 October 2010). "Multidisciplinary care for Guillain-Barré syndrome.". <i>The Cochrane database of systematic reviews</i> (10): CD008505. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2F14651858.CD008505.pub2">10.1002/14651858.CD008505.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20927774">20927774</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Multidisciplinary+care+for+Guillain-Barr%C3%A9+syndrome.&amp;rft.au=Amatya%2C+B&amp;rft.au=Brand%2C+C&amp;rft.aufirst=F&amp;rft.au=Khan%2C+F&amp;rft.aulast=Khan&amp;rft.au=Ng%2C+L&amp;rft.au=Turner-Stokes%2C+L&amp;rft.date=6+October+2010&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD008505.pub2&amp;rft_id=info%3Apmid%2F20927774&amp;rft.issue=10&amp;rft.jtitle=The+Cochrane+database+of+systematic+reviews&amp;rft.pages=CD008505&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Dimachkie2013-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-Dimachkie2013_24-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Dimachkie MM, Barohn RJ (May 2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3939842">"Guillain-Barré syndrome and variants"</a>. <i>Neurology Clinics</i> <b>31</b> (2): 491–510. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.ncl.2013.01.005">10.1016/j.ncl.2013.01.005</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3939842">3939842</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23642721">23642721</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Guillain-Barr%C3%A9+syndrome+and+variants&amp;rft.au=Dimachkie+MM%2C+Barohn+RJ&amp;rft.aulast=Dimachkie+MM%2C+Barohn+RJ&amp;rft.date=May+2013&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3939842&amp;rft_id=info%3Adoi%2F10.1016%2Fj.ncl.2013.01.005&amp;rft_id=info%3Apmc%2F3939842&amp;rft_id=info%3Apmid%2F23642721&amp;rft.issue=2&amp;rft.jtitle=Neurology+Clinics&amp;rft.pages=491-510&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=31" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-25">^</a></b></span> <span class="reference-text"><span class="citation journal">Hughes RA, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA (Sep 2007). <a rel="nofollow" class="external text" href="http://brain.oxfordjournals.org/content/130/9/2245">"Immunotherapy for Guillain-Barré syndrome: a systematic review"</a>. <i>Brain</i> <b>130</b>: 2245–57. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1093%2Fbrain%2Fawm004">10.1093/brain/awm004</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17337484">17337484</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Immunotherapy+for+Guillain-Barr%C3%A9+syndrome%3A+a+systematic+review&amp;rft.au=Hughes+RA%2C+Swan+AV%2C+Rapha%C3%ABl+JC%2C+Annane+D%2C+van+Koningsveld+R%2C+van+Doorn+PA&amp;rft.aulast=Hughes+RA%2C+Swan+AV%2C+Rapha%C3%ABl+JC%2C+Annane+D%2C+van+Koningsveld+R%2C+van+Doorn+PA&amp;rft.date=Sep+2007&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbrain.oxfordjournals.org%2Fcontent%2F130%2F9%2F2245&amp;rft_id=info%3Adoi%2F10.1093%2Fbrain%2Fawm004&amp;rft_id=info%3Apmid%2F17337484&amp;rft.jtitle=Brain&amp;rft.pages=2245-57&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=130" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Darweesh2014-26"><span class="mw-cite-backlink">^ <a href="#cite_ref-Darweesh2014_26-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Darweesh2014_26-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Darweesh, Sirwan K. L.; Polinder, Suzanne; Mulder, Maxim J. H. L.; Baena, Cristina P.; van Leeuwen, Nikki; Franco, Oscar H.; Jacobs, Bart C.; van Doorn, Pieter A. (March 2014). "Health-related quality of life in Guillain-Barré syndrome patients: a systematic review". <i>Journal of the Peripheral Nervous System</i> <b>19</b> (1): 24–35. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fjns5.12051">10.1111/jns5.12051</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24456426">24456426</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Health-related+quality+of+life+in+Guillain-Barr%C3%A9+syndrome+patients%3A+a+systematic+review&amp;rft.au=Baena%2C+Cristina+P.&amp;rft.au=Darweesh%2C+Sirwan+K.+L.&amp;rft.aufirst=Sirwan+K.+L.&amp;rft.au=Franco%2C+Oscar+H.&amp;rft.au=Jacobs%2C+Bart+C.&amp;rft.aulast=Darweesh&amp;rft.au=Mulder%2C+Maxim+J.+H.+L.&amp;rft.au=Polinder%2C+Suzanne&amp;rft.au=van+Doorn%2C+Pieter+A.&amp;rft.au=van+Leeuwen%2C+Nikki&amp;rft.date=March+2014&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fjns5.12051&amp;rft_id=info%3Apmid%2F24456426&amp;rft.issue=1&amp;rft.jtitle=Journal+of+the+Peripheral+Nervous+System&amp;rft.pages=24-35&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=19" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Sejvar2011-27"><span class="mw-cite-backlink">^ <a href="#cite_ref-Sejvar2011_27-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Sejvar2011_27-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Sejvar, James J.; Baughman, Andrew L.; Wise, Matthew; Morgan, Oliver W. (2011). <a rel="nofollow" class="external text" href="http://www.karger.com/Article/FullText/324710">"Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis"</a>. <i>Neuroepidemiology</i> <b>36</b> (2): 123–133. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1159%2F000324710">10.1159/000324710</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21422765">21422765</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Population+incidence+of+Guillain-Barr%C3%A9+syndrome%3A+a+systematic+review+and+meta-analysis&amp;rft.au=Baughman%2C+Andrew+L.&amp;rft.aufirst=James+J.&amp;rft.aulast=Sejvar&amp;rft.au=Morgan%2C+Oliver+W.&amp;rft.au=Sejvar%2C+James+J.&amp;rft.au=Wise%2C+Matthew&amp;rft.date=2011&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.karger.com%2FArticle%2FFullText%2F324710&amp;rft_id=info%3Adoi%2F10.1159%2F000324710&amp;rft_id=info%3Apmid%2F21422765&amp;rft.issue=2&amp;rft.jtitle=Neuroepidemiology&amp;rft.pages=123-133&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=36" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-28"><span class="mw-cite-backlink"><b><a href="#cite_ref-28">^</a></b></span> <span class="reference-text"><span class="citation journal">Goetz, C. G. (1 May 1998). "Georges Guillain's neurologic exploration of America". <i>Neurology</i> <b>50</b> (5): 1451–1455. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1212%2FWNL.50.5.1451">10.1212/WNL.50.5.1451</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9596004">9596004</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Georges+Guillain%27s+neurologic+exploration+of+America&amp;rft.aufirst=C.+G.&amp;rft.au=Goetz%2C+C.+G.&amp;rft.aulast=Goetz&amp;rft.date=1+May+1998&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1212%2FWNL.50.5.1451&amp;rft_id=info%3Apmid%2F9596004&amp;rft.issue=5&amp;rft.jtitle=Neurology&amp;rft.pages=1451-1455&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=50" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-29">^</a></b></span> <span class="reference-text"><span class="citation journal">Landry, Jean-Baptiste (1859). <a rel="nofollow" class="external text" href="https://books.google.ca/books?id=rwxAAAAAcAAJ&amp;pg=PA486">"Note sur la paralysie ascendante aigue"</a>. <i>Gazette Hebdomadaire de Médecine et de Chirurgie</i> <b>6</b>: 472–474, 486–488.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Note+sur+la+paralysie+ascendante+aigue&amp;rft.aufirst=Jean-Baptiste&amp;rft.au=Landry%2C+Jean-Baptiste&amp;rft.aulast=Landry&amp;rft.date=1859&amp;rft.genre=article&amp;rft_id=https%3A%2F%2Fbooks.google.ca%2Fbooks%3Fid%3DrwxAAAAAcAAJ%26pg%3DPA486&amp;rft.jtitle=Gazette+Hebdomadaire+de+M%C3%A9decine+et+de+Chirurgie&amp;rft.pages=472-474%2C+486-488&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=6" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Guillain1916-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-Guillain1916_30-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Guillain, G.; Barré, J.; Strohl, A. (1916). "Sur un syndrome de radiculonévrite avec hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire. Remarques sur les caractères cliniques et graphiques des réflexes tendineux". <i>Bulletins et mémoires de la Société des Médecins des Hôpitaux de Paris</i> <b>40</b>: 1462–70.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Sur+un+syndrome+de+radiculon%C3%A9vrite+avec+hyperalbuminose+du+liquide+c%C3%A9phalo-rachidien+sans+r%C3%A9action+cellulaire.+Remarques+sur+les+caract%C3%A8res+cliniques+et+graphiques+des+r%C3%A9flexes+tendineux&amp;rft.au=Barr%C3%A9%2C+J.&amp;rft.aufirst=G.&amp;rft.au=Guillain%2C+G.&amp;rft.aulast=Guillain&amp;rft.au=Strohl%2C+A.&amp;rft.date=1916&amp;rft.genre=article&amp;rft.jtitle=Bulletins+et+m%C3%A9moires+de+la+Soci%C3%A9t%C3%A9+des+M%C3%A9decins+des+H%C3%B4pitaux+de+Paris&amp;rft.pages=1462-70&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=40" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-31">^</a></b></span> <span class="reference-text"><span class="citation journal">Fisher M (1956). "An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmolplegia, ataxia and areflexia)". <i>N. Engl. J. Med.</i> <b>255</b> (2): 57–65. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJM195607122550201">10.1056/NEJM195607122550201</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/13334797">13334797</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=An+unusual+variant+of+acute+idiopathic+polyneuritis+%28syndrome+of+ophthalmolplegia%2C+ataxia+and+areflexia%29&amp;rft.au=Fisher+M&amp;rft.aulast=Fisher+M&amp;rft.date=1956&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJM195607122550201&amp;rft_id=info%3Apmid%2F13334797&amp;rft.issue=2&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=57-65&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=255" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-32"><span class="mw-cite-backlink"><b><a href="#cite_ref-32">^</a></b></span> <span class="reference-text"><span class="citation journal">Bickerstaff, E.R.; Cloake, P.C. (14 July 1951). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2069534">"Mesencephalitis and rhombencephalitis."</a>. <i>British Medical Journal</i> <b>2</b> (4723): 77–81. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1136%2Fbmj.2.4723.77">10.1136/bmj.2.4723.77</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2069534">2069534</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14848512">14848512</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Mesencephalitis+and+rhombencephalitis.&amp;rft.au=Bickerstaff%2C+E.R.&amp;rft.au=Cloake%2C+P.C.&amp;rft.aufirst=E.R.&amp;rft.aulast=Bickerstaff&amp;rft.date=14+July+1951&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2069534&amp;rft_id=info%3Adoi%2F10.1136%2Fbmj.2.4723.77&amp;rft_id=info%3Apmc%2F2069534&amp;rft_id=info%3Apmid%2F14848512&amp;rft.issue=4723&amp;rft.jtitle=British+Medical+Journal&amp;rft.pages=77-81&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=2" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-33">^</a></b></span> <span class="reference-text"><span class="citation journal">Bickerstaff, E.R. (15 June 1957). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1973653">"Brain-stem encephalitis; further observations on a grave syndrome with benign prognosis."</a>. <i>British Medical Journal</i> <b>1</b> (5032): 1384–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1136%2Fbmj.1.5032.1384">10.1136/bmj.1.5032.1384</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1973653">1973653</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/13436795">13436795</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Brain-stem+encephalitis%3B+further+observations+on+a+grave+syndrome+with+benign+prognosis.&amp;rft.au=Bickerstaff%2C+E.R.&amp;rft.aufirst=E.R.&amp;rft.aulast=Bickerstaff&amp;rft.date=15+June+1957&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1973653&amp;rft_id=info%3Adoi%2F10.1136%2Fbmj.1.5032.1384&amp;rft_id=info%3Apmc%2F1973653&amp;rft_id=info%3Apmid%2F13436795&amp;rft.issue=5032&amp;rft.jtitle=British+Medical+Journal&amp;rft.pages=1384-7&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=1" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-34">^</a></b></span> <span class="reference-text"><span class="citation journal">Asbury, Arthur K.; Cornblath, David R. (1990). "Assessment of current diagnostic criteria for Guillain-Barré syndrome.". <i>Annals of Neurology</i>. 27 Suppl: S21–4. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2Fana.410270707">10.1002/ana.410270707</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/2194422">2194422</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Assessment+of+current+diagnostic+criteria+for+Guillain-Barr%C3%A9+syndrome.&amp;rft.au=Asbury%2C+Arthur+K.&amp;rft.au=Cornblath%2C+David+R.&amp;rft.aufirst=Arthur+K.&amp;rft.aulast=Asbury&amp;rft.date=1990&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2Fana.410270707&amp;rft_id=info%3Apmid%2F2194422&amp;rft.jtitle=Annals+of+Neurology&amp;rft.pages=S21-4&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=27+Suppl" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-35">^</a></b></span> <span class="reference-text"><span class="citation journal">Sejvar, James J.; Kohl, Katrin S.; Gidudu, Jane; Amato, Anthony; Bakshi, Nandini; Baxter, Roger; Burwen, Dale R.; Cornblath, David R.; Cleerbout, Jan; Edwards, Kathryn M.; Heininger, Ulrich; Hughes, Richard; Khuri-Bulos, Najwa; Korinthenberg, Rudolf; Law, Barbara J.; Munro, Ursula; Maltezou, Helena C.; Nell, Patricia; Oleske, James; Sparks, Robert; Velentgas, Priscilla; Vermeer, Patricia; Wiznitzer, Max (January 2011). "Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data". <i>Vaccine</i> <b>29</b> (3): 599–612. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.vaccine.2010.06.003">10.1016/j.vaccine.2010.06.003</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20600491">20600491</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Guillain%E2%80%93Barr%C3%A9+syndrome+and+Fisher+syndrome%3A+Case+definitions+and+guidelines+for+collection%2C+analysis%2C+and+presentation+of+immunization+safety+data&amp;rft.au=Amato%2C+Anthony&amp;rft.au=Bakshi%2C+Nandini&amp;rft.au=Baxter%2C+Roger&amp;rft.au=Burwen%2C+Dale+R.&amp;rft.au=Cleerbout%2C+Jan&amp;rft.au=Cornblath%2C+David+R.&amp;rft.au=Edwards%2C+Kathryn+M.&amp;rft.aufirst=James+J.&amp;rft.au=Gidudu%2C+Jane&amp;rft.au=Heininger%2C+Ulrich&amp;rft.au=Hughes%2C+Richard&amp;rft.au=Khuri-Bulos%2C+Najwa&amp;rft.au=Kohl%2C+Katrin+S.&amp;rft.au=Korinthenberg%2C+Rudolf&amp;rft.aulast=Sejvar&amp;rft.au=Law%2C+Barbara+J.&amp;rft.au=Maltezou%2C+Helena+C.&amp;rft.au=Munro%2C+Ursula&amp;rft.au=Nell%2C+Patricia&amp;rft.au=Oleske%2C+James&amp;rft.au=Sejvar%2C+James+J.&amp;rft.au=Sparks%2C+Robert&amp;rft.au=Velentgas%2C+Priscilla&amp;rft.au=Vermeer%2C+Patricia&amp;rft.au=Wiznitzer%2C+Max&amp;rft.date=January+2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.vaccine.2010.06.003&amp;rft_id=info%3Apmid%2F20600491&amp;rft.issue=3&amp;rft.jtitle=Vaccine&amp;rft.pages=599-612&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=29" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Walgaard2011-36"><span class="mw-cite-backlink">^ <a href="#cite_ref-Walgaard2011_36-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Walgaard2011_36-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Walgaard2011_36-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Walgaard2011_36-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Walgaard2011_36-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Walgaard2011_36-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Walgaard2011_36-6"><sup><i><b>g</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Walgaard, Christa; Jacobs, Bart C; van Doorn, Pieter A (March 2011). "Emerging drugs for Guillain-Barré syndrome". <i>Expert Opinion on Emerging Drugs</i> <b>16</b> (1): 105–120. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1517%2F14728214.2011.531699">10.1517/14728214.2011.531699</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21352072">21352072</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.atitle=Emerging+drugs+for+Guillain-Barr%C3%A9+syndrome&amp;rft.aufirst=Christa&amp;rft.au=Jacobs%2C+Bart+C&amp;rft.aulast=Walgaard&amp;rft.au=van+Doorn%2C+Pieter+A&amp;rft.au=Walgaard%2C+Christa&amp;rft.date=March+2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1517%2F14728214.2011.531699&amp;rft_id=info%3Apmid%2F21352072&amp;rft.issue=1&amp;rft.jtitle=Expert+Opinion+on+Emerging+Drugs&amp;rft.pages=105-120&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=16" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
</ol>
</div>
<h2><span class="mw-headline" id="Further_reading">Further reading</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=21" title="Edit section: Further reading">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><span class="citation book">Steinberg, Gareth J. Parry, Joel S. (2006). <i>Guillain-Barré syndrome: from diagnosis to recovery (American Academy of Neurology)</i>. New York, N.Y.: Pub Group West. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-1932603569" title="Special:BookSources/978-1932603569">978-1932603569</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGuillain%E2%80%93Barr%C3%A9+syndrome&amp;rft.aufirst=Gareth+J.+Parry%2C+Joel+S.&amp;rft.aulast=Steinberg&amp;rft.au=Steinberg%2C+Gareth+J.+Parry%2C+Joel+S.&amp;rft.btitle=Guillain-Barr%C3%A9+syndrome%3A+from+diagnosis+to+recovery+%28American+Academy+of+Neurology%29&amp;rft.date=2006&amp;rft.genre=book&amp;rft.isbn=978-1932603569&amp;rft.place=New+York%2C+N.Y.&amp;rft.pub=Pub+Group+West&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></li>
</ul>
<h2><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit&amp;section=22" title="Edit section: External links">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><a rel="nofollow" class="external text" href="https://www.dmoz.org/Health/Conditions_and_Diseases/Neurological_Disorders/Demyelinating_Diseases/Guillain-Barre_Syndrome/">Guillain–Barré syndrome</a> at <a href="/wiki/DMOZ" title="DMOZ">DMOZ</a></li>
<li><a rel="nofollow" class="external text" href="http://www.gbs-cidp.org/">GBS/CIDP Foundation International</a></li>
</ul>
<table class="navbox" style="border-spacing:0">
<tr>
<td style="padding:2px">
<table class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:PNS_diseases_of_the_nervous_system" title="Template:PNS diseases of the nervous system"><span title="View this template" style=";;background:none transparent;border:none;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:PNS_diseases_of_the_nervous_system" title="Template talk:PNS diseases of the nervous system"><span title="Discuss this template" style=";;background:none transparent;border:none;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:PNS_diseases_of_the_nervous_system&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%"><a href="/wiki/Nervous_system" title="Nervous system">Nervous system</a> <a href="/wiki/Pathology" title="Pathology">pathology</a>, <a href="/wiki/Peripheral_neuropathy" title="Peripheral neuropathy">PNS</a>, <a href="/wiki/Somatic_nervous_system" title="Somatic nervous system">somatic</a> (<a href="/wiki/ICD-10_Chapter_VI:_Diseases_of_the_nervous_system#.28G50.E2.80.93G59.29_Nerve.2C_nerve_root_and_plexus_disorders" title="ICD-10 Chapter VI: Diseases of the nervous system">G50–G64</a>, <a href="/wiki/List_of_ICD-9_codes_320%E2%80%93359:_diseases_of_the_nervous_system#Disorders_of_the_peripheral_nervous_system_.28350.E2.80.93359.29" title="List of ICD-9 codes 320–359: diseases of the nervous system">350–357</a>)</div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td colspan="2" class="navbox-list navbox-odd hlist" style="width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks collapsible uncollapsed navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="col" class="navbox-title" colspan="2" style=";padding-left: 0.5em; padding-right: 0.75em"><span style="float:left;width:6em">&#160;</span>
<div style="font-size:110%"><a href="/wiki/Nervous_system" title="Nervous system">Nerve</a>, nerve root, <a href="/wiki/Plexus" title="Plexus">plexus</a></div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Cranial_nerve_disease" title="Cranial nerve disease">Cranial nerve<br />
disease</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i><a href="/wiki/Trigeminal_nerve" title="Trigeminal nerve">V</a></i> <a href="/wiki/Trigeminal_neuralgia" title="Trigeminal neuralgia">Trigeminal neuralgia</a></li>
<li><a href="/wiki/Anesthesia_dolorosa" title="Anesthesia dolorosa">Anesthesia dolorosa</a></li>
<li><i><a href="/wiki/Facial_nerve" title="Facial nerve">VII</a></i> <a href="/wiki/Facial_nerve_paralysis" title="Facial nerve paralysis">Facial nerve paralysis</a></li>
<li><a href="/wiki/Bell%27s_palsy" title="Bell's palsy">Bell's palsy</a></li>
<li><a href="/wiki/Melkersson%E2%80%93Rosenthal_syndrome" title="Melkersson–Rosenthal syndrome">Melkersson–Rosenthal syndrome</a></li>
<li><a href="/wiki/Parry%E2%80%93Romberg_syndrome" title="Parry–Romberg syndrome">Parry–Romberg syndrome</a></li>
<li><a href="/wiki/Central_facial_palsy" title="Central facial palsy">Central seven</a></li>
<li><i><a href="/wiki/Accessory_nerve" title="Accessory nerve">XI</a></i> <a href="/wiki/Accessory_nerve_disorder" title="Accessory nerve disorder">Accessory nerve disorder</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Radiculopathy" title="Radiculopathy">Radiculopathy</a>,<br />
<a href="/wiki/Plexopathy" title="Plexopathy">plexopathy</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i><a href="/wiki/Brachial_plexus" title="Brachial plexus">brachial plexus</a></i> <a href="/wiki/Brachial_plexus_injury" title="Brachial plexus injury">Brachial plexus lesion</a></li>
<li><a href="/wiki/Thoracic_outlet_syndrome" title="Thoracic outlet syndrome">Thoracic outlet syndrome</a></li>
<li><a href="/wiki/Phantom_limb" title="Phantom limb">Phantom limb</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Mononeuropathy" title="Mononeuropathy" class="mw-redirect">Mono-</a><br />
<a href="/wiki/Neuropathy" title="Neuropathy" class="mw-redirect">neuropathy</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Upper_limb" title="Upper limb">Upper limb</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Median_nerve" title="Median nerve">median nerve</a>:</i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Carpal_tunnel_syndrome" title="Carpal tunnel syndrome">Carpal tunnel syndrome</a></li>
<li><a href="/wiki/Ape_hand_deformity" title="Ape hand deformity">Ape hand deformity</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Ulnar_nerve" title="Ulnar nerve">ulnar nerve</a>:</i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Ulnar_nerve_entrapment" title="Ulnar nerve entrapment">Ulnar nerve entrapment</a></li>
<li><a href="/wiki/Froment%27s_sign" title="Froment's sign">Froment's sign</a></li>
<li><a href="/wiki/Guyon%27s_canal_syndrome" title="Guyon's canal syndrome" class="mw-redirect">Guyon's canal syndrome</a></li>
<li><a href="/wiki/Ulnar_claw" title="Ulnar claw">Ulnar claw</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Radial_nerve" title="Radial nerve">radial nerve</a>:</i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Radial_neuropathy" title="Radial neuropathy">Radial neuropathy</a></li>
<li><a href="/wiki/Wrist_drop" title="Wrist drop">Wrist drop</a></li>
<li><a href="/wiki/Cheiralgia_paresthetica" title="Cheiralgia paresthetica">Cheiralgia paresthetica</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Long_thoracic_nerve" title="Long thoracic nerve">long thoracic nerve</a>:</i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Winged_scapula" title="Winged scapula">Winged scapula</a></li>
<li><a href="/wiki/Backpack_palsy" title="Backpack palsy">Backpack palsy</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Lower_limb" title="Lower limb" class="mw-redirect">Lower limb</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Lateral_cutaneous_nerve_of_thigh" title="Lateral cutaneous nerve of thigh">lateral cutaneous nerve of thigh</a>:</i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Meralgia_paraesthetica" title="Meralgia paraesthetica">Meralgia paraesthetica</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Tibial_nerve" title="Tibial nerve">tibial nerve</a>:</i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Tarsal_tunnel_syndrome" title="Tarsal tunnel syndrome">Tarsal tunnel syndrome</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Plantar_nerve" title="Plantar nerve">plantar nerve</a>:</i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Morton%27s_neuroma" title="Morton's neuroma">Morton's neuroma</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Superior_gluteal_nerve" title="Superior gluteal nerve">superior gluteal nerve</a>:</i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Trendelenburg%27s_sign" title="Trendelenburg's sign">Trendelenburg's sign</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Sciatic_nerve" title="Sciatic nerve">sciatic nerve</a>:</i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Piriformis_syndrome" title="Piriformis syndrome">Piriformis syndrome</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">General</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Complex_regional_pain_syndrome" title="Complex regional pain syndrome">Causalgia</a></li>
<li><a href="/wiki/Mononeuritis_multiplex" title="Mononeuritis multiplex" class="mw-redirect">Mononeuritis multiplex</a></li>
<li><a href="/wiki/Peripheral_neuropathy" title="Peripheral neuropathy">Neuropathy</a> <a href="/wiki/Neuralgia" title="Neuralgia">Neuralgia</a>/<a href="/wiki/Peripheral_neuropathy" title="Peripheral neuropathy">Neuritis</a></li>
<li><a href="/wiki/Nerve_compression_syndrome" title="Nerve compression syndrome">Nerve compression syndrome</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td colspan="2" class="navbox-list navbox-even hlist" style="width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks collapsible uncollapsed navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="col" class="navbox-title" colspan="2" style=";padding-left: 0.5em; padding-right: 0.75em"><span style="float:left;width:6em">&#160;</span>
<div style="font-size:110%"><a href="/wiki/Polyneuropathy" title="Polyneuropathy">Polyneuropathies</a>/<a href="/wiki/Polyradiculoneuropathy" title="Polyradiculoneuropathy">Polyradiculoneuropathy</a></div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Hereditary_motor_and_sensory_neuropathy" title="Hereditary motor and sensory neuropathy">HMSN</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Charcot%E2%80%93Marie%E2%80%93Tooth_disease" title="Charcot–Marie–Tooth disease">Charcot–Marie–Tooth disease</a></li>
<li><a href="/wiki/Dejerine%E2%80%93Sottas_disease" title="Dejerine–Sottas disease">Dejerine–Sottas disease</a></li>
<li><a href="/wiki/Refsum_disease" title="Refsum disease">Refsum's disease</a></li>
<li><a href="/wiki/Hereditary_spastic_paraplegia" title="Hereditary spastic paraplegia">Hereditary spastic paraplegia</a></li>
<li><a href="/wiki/Hereditary_neuropathy_with_liability_to_pressure_palsy" title="Hereditary neuropathy with liability to pressure palsy">Hereditary neuropathy with liability to pressure palsy</a></li>
<li><a href="/wiki/Familial_amyloid_neuropathy" title="Familial amyloid neuropathy">Familial amyloid neuropathy</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Autoimmunity" title="Autoimmunity">Autoimmune</a>/<a href="/wiki/Demyelinating_disease" title="Demyelinating disease">demyelinating</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><strong class="selflink">Guillain–Barré syndrome</strong></li>
<li><a href="/wiki/Chronic_inflammatory_demyelinating_polyneuropathy" title="Chronic inflammatory demyelinating polyneuropathy">Chronic inflammatory demyelinating polyneuropathy</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Other</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Alcoholic_polyneuropathy" title="Alcoholic polyneuropathy">Alcoholic polyneuropathy</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;">
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Peripheral_nervous_system_navs" title="Template:Peripheral nervous system navs"><span title="View this template" style=";;background:none transparent;border:none;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Peripheral_nervous_system_navs" title="Template talk:Peripheral nervous system navs"><span title="Discuss this template" style=";;background:none transparent;border:none;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Peripheral_nervous_system_navs&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%">Index of the <a href="/wiki/Peripheral_nervous_system" title="Peripheral nervous system">peripheral nervous system</a></div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Description</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Nervous_system" title="Template:Nervous system">Anatomy</a></li>
<li><a href="/wiki/Template:Nervous_tissue" title="Template:Nervous tissue">Nerves</a>
<ul>
<li><a href="/wiki/Template:Cranial_nerves" title="Template:Cranial nerves">cranial</a></li>
<li><a href="/wiki/Template:Trigeminal_nerve" title="Template:Trigeminal nerve">trigeminal</a></li>
<li><a href="/wiki/Template:Cervical_plexus" title="Template:Cervical plexus">cervical</a></li>
<li><a href="/wiki/Template:Brachial_plexus" title="Template:Brachial plexus">brachial</a></li>
<li><a href="/wiki/Template:Lumbosacral_plexus" title="Template:Lumbosacral plexus">lumbosacral plexus</a></li>
<li><a href="/wiki/Template:Somatosensory_system" title="Template:Somatosensory system">somatosensory</a></li>
<li><a href="/wiki/Template:Spinal_nerves" title="Template:Spinal nerves">spinal</a></li>
<li><a href="/wiki/Template:Autonomic_nervous_system" title="Template:Autonomic nervous system">autonomic</a></li>
</ul>
</li>
<li><a href="/wiki/Template:Nervous_system_physiology" title="Template:Nervous system physiology">Physiology</a>
<ul>
<li><a href="/wiki/Template:Reflex" title="Template:Reflex">reflexes</a></li>
<li><a href="/wiki/Template:Nerve_tissue_protein" title="Template:Nerve tissue protein">proteins</a></li>
<li><a href="/wiki/Template:Neurotransmitters" title="Template:Neurotransmitters">neurotransmitters</a></li>
<li><a href="/wiki/Template:Neurotransmitter_transporters" title="Template:Neurotransmitter transporters">transporters</a></li>
</ul>
</li>
<li><a href="/wiki/Template:Development_of_nervous_system" title="Template:Development of nervous system">Development</a>
<ul>
<li><a href="/wiki/Template:Neurotrophins" title="Template:Neurotrophins">neurotrophins</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Disease</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Autonomic_diseases" title="Template:Autonomic diseases">Autonomic</a></li>
<li><a href="/wiki/Template:Congenital_malformations_and_deformations_of_nervous_system" title="Template:Congenital malformations and deformations of nervous system">Congenital</a></li>
<li><a href="/wiki/Template:Neurotrauma" title="Template:Neurotrauma">Injury</a></li>
<li><a href="/wiki/Template:Nervous_system_tumors" title="Template:Nervous system tumors">Neoplasms and cancer</a></li>
<li><a href="/wiki/Template:PNS_diseases_of_the_nervous_system" title="Template:PNS diseases of the nervous system">Other</a></li>
<li><a href="/wiki/Template:Nervous_and_musculoskeletal_system_symptoms_and_signs" title="Template:Nervous and musculoskeletal system symptoms and signs">Symptoms and signs</a>
<ul>
<li><a href="/wiki/Template:Eponymous_medical_signs_for_nervous_system" title="Template:Eponymous medical signs for nervous system">eponymous</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Treatment</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Neuro_procedures" title="Template:Neuro procedures">Procedures</a></li>
<li><a href="/wiki/Template:Local_anesthetics" title="Template:Local anesthetics">Local anesthetics</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table class="navbox" style="border-spacing:0">
<tr>
<td style="padding:2px">
<table class="nowraplinks hlist collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Hypersensitivity_and_autoimmune_diseases" title="Template:Hypersensitivity and autoimmune diseases"><span title="View this template" style=";;background:none transparent;border:none;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Hypersensitivity_and_autoimmune_diseases" title="Template talk:Hypersensitivity and autoimmune diseases"><span title="Discuss this template" style=";;background:none transparent;border:none;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Hypersensitivity_and_autoimmune_diseases&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%"><a href="/wiki/Hypersensitivity" title="Hypersensitivity">Hypersensitivity</a> and <a href="/wiki/Autoimmune_disease" title="Autoimmune disease">autoimmune diseases</a> (<a href="/wiki/List_of_ICD-9_codes_240%E2%80%93279:_endocrine,_nutritional_and_metabolic_diseases,_and_immunity_disorders" title="List of ICD-9 codes 240–279: endocrine, nutritional and metabolic diseases, and immunity disorders">279.5–6</a>)</div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Type_I_hypersensitivity" title="Type I hypersensitivity">Type I</a>/<a href="/wiki/Allergy" title="Allergy">allergy</a>/<a href="/wiki/Atopy" title="Atopy">atopy</a><br />
(<a href="/wiki/Immunoglobulin_E" title="Immunoglobulin E">IgE</a>)</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group">Foreign</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Atopic_eczema" title="Atopic eczema" class="mw-redirect">Atopic eczema</a></li>
<li><a href="/wiki/Urticaria" title="Urticaria">Allergic urticaria</a></li>
<li><a href="/wiki/Allergic_rhinitis" title="Allergic rhinitis">Allergic rhinitis</a> (Hay fever)</li>
<li><a href="/wiki/Asthma" title="Asthma">Allergic asthma</a></li>
<li><a href="/wiki/Anaphylaxis" title="Anaphylaxis">Anaphylaxis</a></li>
<li><a href="/wiki/Food_allergy" title="Food allergy">Food allergy</a>
<ul>
<li><a href="/wiki/Milk_allergy" title="Milk allergy">Milk</a></li>
<li><a href="/wiki/Egg_allergy" title="Egg allergy">Egg</a></li>
<li><a href="/wiki/Peanut_allergy" title="Peanut allergy">Peanut</a></li>
<li><a href="/wiki/Tree_nut_allergy" title="Tree nut allergy">Tree nut</a></li>
<li><a href="/wiki/Seafood_allergy" title="Seafood allergy">Seafood</a></li>
<li><a href="/wiki/Soy_allergy" title="Soy allergy">Soy</a></li>
<li><a href="/wiki/Wheat_allergy" title="Wheat allergy">Wheat</a></li>
</ul>
</li>
<li><a href="/wiki/Penicillin_drug_reaction" title="Penicillin drug reaction" class="mw-redirect">Penicillin allergy</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Autoimmune</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Eosinophilic_esophagitis" title="Eosinophilic esophagitis">Eosinophilic esophagitis</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Type_II_hypersensitivity" title="Type II hypersensitivity">Type II</a>/<a href="/wiki/Antibody-dependent_cell-mediated_cytotoxicity" title="Antibody-dependent cell-mediated cytotoxicity">ADCC</a><br />
<ul>
<li>
<ul>
<li><a href="/wiki/Immunoglobulin_M" title="Immunoglobulin M">IgM</a></li>
<li><a href="/wiki/Immunoglobulin_G" title="Immunoglobulin G">IgG</a></li>
</ul>
</li>
</ul>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group">Foreign</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Hemolytic_disease_of_the_newborn" title="Hemolytic disease of the newborn">Hemolytic disease of the newborn</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Autoimmune</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Cytotoxicity" title="Cytotoxicity">Cytotoxic</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Autoimmune_hemolytic_anemia" title="Autoimmune hemolytic anemia">Autoimmune hemolytic anemia</a></li>
<li><a href="/wiki/Idiopathic_thrombocytopenic_purpura" title="Idiopathic thrombocytopenic purpura">Idiopathic thrombocytopenic purpura</a></li>
<li><a href="/wiki/Bullous_pemphigoid" title="Bullous pemphigoid">Bullous pemphigoid</a></li>
<li><a href="/wiki/Pemphigus_vulgaris" title="Pemphigus vulgaris">Pemphigus vulgaris</a></li>
<li><a href="/wiki/Rheumatic_fever" title="Rheumatic fever">Rheumatic fever</a></li>
<li><a href="/wiki/Goodpasture%27s_syndrome" title="Goodpasture's syndrome" class="mw-redirect">Goodpasture's syndrome</a></li>
<li><strong class="selflink">Guillain–Barré syndrome</strong></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">"<a href="/wiki/Hypersensitivity#Type_V" title="Hypersensitivity">Type V</a>"/<a href="/wiki/Receptor_(biochemistry)" title="Receptor (biochemistry)">receptor</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Graves%27_disease" title="Graves' disease">Graves' disease</a></li>
<li><a href="/wiki/Myasthenia_gravis" title="Myasthenia gravis">Myasthenia gravis</a></li>
<li><a href="/wiki/Pernicious_anemia" title="Pernicious anemia">Pernicious anemia</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Type_III_hypersensitivity" title="Type III hypersensitivity">Type III</a><br />
(<a href="/wiki/Immune_complex" title="Immune complex">Immune complex</a>)</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group">Foreign</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Henoch%E2%80%93Sch%C3%B6nlein_purpura" title="Henoch–Schönlein purpura">Henoch–Schönlein purpura</a></li>
<li><a href="/wiki/Cutaneous_small-vessel_vasculitis" title="Cutaneous small-vessel vasculitis">Hypersensitivity vasculitis</a></li>
<li><a href="/wiki/Reactive_arthritis" title="Reactive arthritis">Reactive arthritis</a></li>
<li><a href="/wiki/Farmer%27s_lung" title="Farmer's lung">Farmer's lung</a></li>
<li><a href="/wiki/Acute_proliferative_glomerulonephritis" title="Acute proliferative glomerulonephritis">Post-streptococcal glomerulonephritis</a></li>
<li><a href="/wiki/Serum_sickness" title="Serum sickness">Serum sickness</a></li>
<li><a href="/wiki/Arthus_reaction" title="Arthus reaction">Arthus reaction</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Autoimmune</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Systemic_lupus_erythematosus" title="Systemic lupus erythematosus">Systemic lupus erythematosus</a></li>
<li><a href="/wiki/Subacute_bacterial_endocarditis" title="Subacute bacterial endocarditis">Subacute bacterial endocarditis</a></li>
<li><a href="/wiki/Rheumatoid_arthritis" title="Rheumatoid arthritis">Rheumatoid arthritis</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Type_IV_hypersensitivity" title="Type IV hypersensitivity">Type IV</a>/<a href="/wiki/Cell-mediated_immunity" title="Cell-mediated immunity">cell-mediated</a><br />
(<a href="/wiki/T_cell" title="T cell">T cells</a>)</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group">Foreign</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Allergic_contact_dermatitis" title="Allergic contact dermatitis">Allergic contact dermatitis</a></li>
<li><a href="/wiki/Mantoux_test" title="Mantoux test">Mantoux test</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Autoimmune</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Diabetes_mellitus_type_1" title="Diabetes mellitus type 1">Diabetes mellitus type 1</a></li>
<li><a href="/wiki/Hashimoto%27s_thyroiditis" title="Hashimoto's thyroiditis">Hashimoto's thyroiditis</a></li>
<li><a href="/wiki/Multiple_sclerosis" title="Multiple sclerosis">Multiple sclerosis</a></li>
<li><a href="/wiki/Coeliac_disease" title="Coeliac disease">Coeliac disease</a></li>
<li><a href="/wiki/Giant-cell_arteritis" title="Giant-cell arteritis">Giant-cell arteritis</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Graft-versus-host_disease" title="Graft-versus-host disease">GVHD</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Transfusion-associated_graft_versus_host_disease" title="Transfusion-associated graft versus host disease">Transfusion-associated graft versus host disease</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Unknown/<br />
multiple</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group">Foreign</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Hypersensitivity_pneumonitis" title="Hypersensitivity pneumonitis">Hypersensitivity pneumonitis</a>
<ul>
<li><a href="/wiki/Allergic_bronchopulmonary_aspergillosis" title="Allergic bronchopulmonary aspergillosis">Allergic bronchopulmonary aspergillosis</a></li>
</ul>
</li>
<li><a href="/wiki/Transplant_rejection" title="Transplant rejection">Transplant rejection</a></li>
<li><a href="/wiki/Latex_allergy" title="Latex allergy">Latex allergy</a> (I+IV)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Autoimmune</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Sj%C3%B6gren%27s_syndrome" title="Sjögren's syndrome">Sjögren's syndrome</a></li>
<li><a href="/wiki/Autoimmune_hepatitis" title="Autoimmune hepatitis">Autoimmune hepatitis</a></li>
<li><a href="/wiki/Autoimmune_polyendocrine_syndrome" title="Autoimmune polyendocrine syndrome">Autoimmune polyendocrine syndrome</a>
<ul>
<li><a href="/wiki/Autoimmune_polyendocrine_syndrome_type_1" title="Autoimmune polyendocrine syndrome type 1">APS1</a></li>
<li><a href="/wiki/Autoimmune_polyendocrine_syndrome_type_2" title="Autoimmune polyendocrine syndrome type 2">APS2</a></li>
</ul>
</li>
<li><a href="/wiki/Addison%27s_disease" title="Addison's disease">Autoimmune adrenalitis</a></li>
<li><a href="/wiki/Autoimmune_disease" title="Autoimmune disease">Systemic autoimmune disease</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;">
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Lymph_immune_and_complement_navs" title="Template:Lymph immune and complement navs"><span title="View this template" style=";;background:none transparent;border:none;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Lymph_immune_and_complement_navs" title="Template talk:Lymph immune and complement navs"><span title="Discuss this template" style=";;background:none transparent;border:none;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Lymph_immune_and_complement_navs&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%">Index of the <a href="/wiki/Immune_system" title="Immune system">immune system</a></div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Description</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Lymphocytic_immune_system" title="Template:Lymphocytic immune system">Physiology</a>
<ul>
<li><a href="/wiki/Template:Lymphocytes" title="Template:Lymphocytes">cells</a></li>
<li><a href="/wiki/Template:Autoantigens" title="Template:Autoantigens">autoantigens</a></li>
<li><a href="/wiki/Template:Autoantibodies" title="Template:Autoantibodies">autoantibodies</a></li>
<li><a href="/wiki/Template:Complement_system" title="Template:Complement system">complement</a></li>
<li><a href="/wiki/Template:Surface_antigens" title="Template:Surface antigens">surface antigens</a></li>
<li><a href="/wiki/Template:Immunoglobulin_superfamily_immune_receptors" title="Template:Immunoglobulin superfamily immune receptors">IG receptors</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Disease</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Allergic_conditions" title="Template:Allergic conditions">Allergies</a></li>
<li><a href="/wiki/Template:Lymphoid_and_complement_immunodeficiency" title="Template:Lymphoid and complement immunodeficiency">Immunodeficiency</a></li>
<li><a href="/wiki/Template:Immunoproliferative_immunoglobulin_disorders" title="Template:Immunoproliferative immunoglobulin disorders">Immunoproliferative immunoglobulin disorders</a></li>
<li><a href="/wiki/Template:Hypersensitivity_and_autoimmune_diseases" title="Template:Hypersensitivity and autoimmune diseases">Hypersensitivity and autoimmune disorders</a></li>
<li><a href="/wiki/Template:Lymphoid_malignancy" title="Template:Lymphoid malignancy">Neoplasms and cancer</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Treatment</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Immunologic_techniques_and_tests" title="Template:Immunologic techniques and tests">Procedures</a></li>
<li>Drugs
<ul>
<li><a href="/wiki/Template:Antihistamines" title="Template:Antihistamines">antihistamines</a></li>
<li><a href="/wiki/Template:Immunostimulants" title="Template:Immunostimulants">immunostimulants</a></li>
<li><a href="/wiki/Template:Immunosuppressants" title="Template:Immunosuppressants">immunosuppressants</a></li>
<li><a href="/wiki/Template:Monoclonals_for_immune_system" title="Template:Monoclonals for immune system">monoclonal antibodies</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
</table>


<!-- 
NewPP limit report
Parsed by mw1099
CPU time usage: 0.845 seconds
Real time usage: 0.932 seconds
Preprocessor visited node count: 5043/1000000
Preprocessor generated node count: 0/1500000
Post‐expand include size: 247136/2097152 bytes
Template argument size: 12627/2097152 bytes
Highest expansion depth: 14/40
Expensive parser function count: 0/500
Lua time usage: 0.271/10.000 seconds
Lua memory usage: 3.62 MB/50 MB
-->

<!-- 
Transclusion expansion time report (%,ms,calls,template)
100.00%  701.425      1 - -total
 41.26%  289.393      1 - Template:Reflist
 26.63%  186.795     36 - Template:Cite_journal
 20.70%  145.225     14 - Template:Navbox
 13.97%   97.994      1 - Template:PNS_diseases_of_the_nervous_system
 13.60%   95.393      1 - Template:Infobox_disease
 13.42%   94.163      1 - Template:Navbox_with_collapsible_groups
 12.12%   85.028      1 - Template:Infobox
  7.09%   49.728      1 - Template:Autoimmune_diseases
  3.38%   23.683      1 - Template:Peripheral_nervous_system_navs
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:12800708-0!*!0!!en!4!* and timestamp 20150711183314 and revision id 670975682
 -->
<noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div>					<div class="printfooter">
						Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Guillain–Barré_syndrome&amp;oldid=670975682">https://en.wikipedia.org/w/index.php?title=Guillain–Barré_syndrome&amp;oldid=670975682</a>"					</div>
				<div id='catlinks' class='catlinks'><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Autoimmune_diseases" title="Category:Autoimmune diseases">Autoimmune diseases</a></li><li><a href="/wiki/Category:Syndromes" title="Category:Syndromes">Syndromes</a></li><li><a href="/wiki/Category:Neurological_disorders" title="Category:Neurological disorders">Neurological disorders</a></li><li><a href="/wiki/Category:Cytomegalovirus-associated_diseases" title="Category:Cytomegalovirus-associated diseases">Cytomegalovirus-associated diseases</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">CS1 maint: Explicit use of et al.</a></li><li><a href="/wiki/Category:Articles_with_contributors_link" title="Category:Articles with contributors link">Articles with contributors link</a></li><li><a href="/wiki/Category:Articles_with_DMOZ_links" title="Category:Articles with DMOZ links">Articles with DMOZ links</a></li><li><a href="/wiki/Category:Articles_that_use_a_Medicine_navs_subtemplate" title="Category:Articles that use a Medicine navs subtemplate">Articles that use a Medicine navs subtemplate</a></li></ul></div></div>				<div class="visualClear"></div>
							</div>
		</div>
		<div id="mw-navigation">
			<h2>Navigation menu</h2>

			<div id="mw-head">
									<div id="p-personal" role="navigation" class="" aria-labelledby="p-personal-label">
						<h3 id="p-personal-label">Personal tools</h3>
						<ul>
							<li id="pt-createaccount"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Guillain%E2%80%93Barr%C3%A9+syndrome&amp;type=signup" title="You are encouraged to create an account and log in; however, it is not mandatory">Create account</a></li><li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Guillain%E2%80%93Barr%C3%A9+syndrome" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o">Log in</a></li>						</ul>
					</div>
									<div id="left-navigation">
										<div id="p-namespaces" role="navigation" class="vectorTabs" aria-labelledby="p-namespaces-label">
						<h3 id="p-namespaces-label">Namespaces</h3>
						<ul>
															<li  id="ca-nstab-main" class="selected"><span><a href="/wiki/Guillain%E2%80%93Barr%C3%A9_syndrome"  title="View the content page [c]" accesskey="c">Article</a></span></li>
															<li  id="ca-talk"><span><a href="/wiki/Talk:Guillain%E2%80%93Barr%C3%A9_syndrome"  title="Discussion about the content page [t]" accesskey="t" rel="discussion">Talk</a></span></li>
													</ul>
					</div>
										<div id="p-variants" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-variants-label">
												<h3 id="p-variants-label">
							<span>Variants</span><a href="#"></a>
						</h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
									</div>
				<div id="right-navigation">
										<div id="p-views" role="navigation" class="vectorTabs" aria-labelledby="p-views-label">
						<h3 id="p-views-label">Views</h3>
						<ul>
															<li id="ca-view" class="selected"><span><a href="/wiki/Guillain%E2%80%93Barr%C3%A9_syndrome" >Read</a></span></li>
															<li id="ca-edit"><span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=edit"  title="Edit this page [e]" accesskey="e">Edit</a></span></li>
															<li id="ca-history" class="collapsible"><span><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=history"  title="Past versions of this page [h]" accesskey="h">View history</a></span></li>
													</ul>
					</div>
										<div id="p-cactions" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-cactions-label">
						<h3 id="p-cactions-label"><span>More</span><a href="#"></a></h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
										<div id="p-search" role="search">
						<h3>
							<label for="searchInput">Search</label>
						</h3>

						<form action="/w/index.php" id="searchform">
							<div id="simpleSearch">
							<input type="search" name="search" placeholder="Search" title="Search Wikipedia [f]" accesskey="f" id="searchInput" /><input type="hidden" value="Special:Search" name="title" /><input type="submit" name="fulltext" value="Search" title="Search Wikipedia for this text" id="mw-searchButton" class="searchButton mw-fallbackSearchButton" /><input type="submit" name="go" value="Go" title="Go to a page with this exact name if one exists" id="searchButton" class="searchButton" />							</div>
						</form>
					</div>
									</div>
			</div>
			<div id="mw-panel">
				<div id="p-logo" role="banner"><a class="mw-wiki-logo" href="/wiki/Main_Page"  title="Visit the main page"></a></div>
						<div class="portal" role="navigation" id='p-navigation' aria-labelledby='p-navigation-label'>
			<h3 id='p-navigation-label'>Navigation</h3>

			<div class="body">
									<ul>
						<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li><li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li><li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content – the best of Wikipedia">Featured content</a></li><li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li><li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li><li id="n-sitesupport"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us">Donate to Wikipedia</a></li><li id="n-shoplink"><a href="//shop.wikimedia.org" title="Visit the Wikimedia Shop">Wikipedia store</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-interaction' aria-labelledby='p-interaction-label'>
			<h3 id='p-interaction-label'>Interaction</h3>

			<div class="body">
									<ul>
						<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li><li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li><li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li><li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="A list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li><li id="n-contactpage"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-tb' aria-labelledby='p-tb-label'>
			<h3 id='p-tb-label'>Tools</h3>

			<div class="body">
									<ul>
						<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Guillain%E2%80%93Barr%C3%A9_syndrome" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li><li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Guillain%E2%80%93Barr%C3%A9_syndrome" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li><li id="t-upload"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li><li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li><li id="t-permalink"><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;oldid=670975682" title="Permanent link to this revision of the page">Permanent link</a></li><li id="t-info"><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;action=info" title="More information about this page">Page information</a></li><li id="t-wikibase"><a href="//www.wikidata.org/wiki/Q205214" title="Link to connected data repository item [g]" accesskey="g">Wikidata item</a></li><li id="t-cite"><a href="/w/index.php?title=Special:CiteThisPage&amp;page=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;id=670975682" title="Information on how to cite this page">Cite this page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-coll-print_export' aria-labelledby='p-coll-print_export-label'>
			<h3 id='p-coll-print_export-label'>Print/export</h3>

			<div class="body">
									<ul>
						<li id="coll-create_a_book"><a href="/w/index.php?title=Special:Book&amp;bookcmd=book_creator&amp;referer=Guillain%E2%80%93Barr%C3%A9+syndrome">Create a book</a></li><li id="coll-download-as-rdf2latex"><a href="/w/index.php?title=Special:Book&amp;bookcmd=render_article&amp;arttitle=Guillain%E2%80%93Barr%C3%A9+syndrome&amp;oldid=670975682&amp;writer=rdf2latex">Download as PDF</a></li><li id="t-print"><a href="/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-lang' aria-labelledby='p-lang-label'>
			<h3 id='p-lang-label'>Languages</h3>

			<div class="body">
									<ul>
						<li class="interlanguage-link interwiki-ar"><a href="//ar.wikipedia.org/wiki/%D9%85%D8%AA%D9%84%D8%A7%D8%B2%D9%85%D8%A9_%D8%BA%D9%8A%D9%84%D8%A7%D9%86_%D8%A8%D8%A7%D8%B1%D9%8A%D9%87" title="متلازمة غيلان باريه – Arabic" lang="ar" hreflang="ar">العربية</a></li><li class="interlanguage-link interwiki-az"><a href="//az.wikipedia.org/wiki/Guillain_Barre_sindromu" title="Guillain Barre sindromu – Azerbaijani" lang="az" hreflang="az">Azərbaycanca</a></li><li class="interlanguage-link interwiki-bn"><a href="//bn.wikipedia.org/wiki/%E0%A6%97%E0%A7%81%E0%A6%B2%E0%A7%87%E0%A6%A8_%E0%A6%AC%E0%A6%BE%E0%A6%B0%E0%A6%BF_%E0%A6%B8%E0%A6%BF%E0%A6%A8%E0%A6%A1%E0%A7%8D%E0%A6%B0%E0%A7%8B%E0%A6%AE" title="গুলেন বারি সিনড্রোম – Bengali" lang="bn" hreflang="bn">বাংলা</a></li><li class="interlanguage-link interwiki-bg"><a href="//bg.wikipedia.org/wiki/%D0%A1%D0%B8%D0%BD%D0%B4%D1%80%D0%BE%D0%BC_%D0%BD%D0%B0_%D0%93%D0%B8%D0%BB%D0%B5%D0%BD-%D0%91%D0%B0%D1%80%D0%B5" title="Синдром на Гилен-Баре – Bulgarian" lang="bg" hreflang="bg">Български</a></li><li class="interlanguage-link interwiki-ca"><a href="//ca.wikipedia.org/wiki/S%C3%ADndrome_de_Guillain-Barr%C3%A9" title="Síndrome de Guillain-Barré – Catalan" lang="ca" hreflang="ca">Català</a></li><li class="interlanguage-link interwiki-cs"><a href="//cs.wikipedia.org/wiki/Guillain-Barr%C3%A9ho_syndrom" title="Guillain-Barrého syndrom – Czech" lang="cs" hreflang="cs">Čeština</a></li><li class="interlanguage-link interwiki-da"><a href="//da.wikipedia.org/wiki/Guillain-Barr%C3%A9s_syndrom" title="Guillain-Barrés syndrom – Danish" lang="da" hreflang="da">Dansk</a></li><li class="interlanguage-link interwiki-de"><a href="//de.wikipedia.org/wiki/Guillain-Barr%C3%A9-Syndrom" title="Guillain-Barré-Syndrom – German" lang="de" hreflang="de">Deutsch</a></li><li class="interlanguage-link interwiki-es"><a href="//es.wikipedia.org/wiki/S%C3%ADndrome_de_Guillain-Barr%C3%A9" title="Síndrome de Guillain-Barré – Spanish" lang="es" hreflang="es">Español</a></li><li class="interlanguage-link interwiki-fa"><a href="//fa.wikipedia.org/wiki/%D9%86%D8%B4%D8%A7%D9%86%DA%AF%D8%A7%D9%86_%DA%AF%DB%8C%D9%84%D9%86_%D8%A8%D8%A7%D8%B1%D9%87" title="نشانگان گیلن باره – Persian" lang="fa" hreflang="fa">فارسی</a></li><li class="interlanguage-link interwiki-fr"><a href="//fr.wikipedia.org/wiki/Syndrome_de_Guillain-Barr%C3%A9" title="Syndrome de Guillain-Barré – French" lang="fr" hreflang="fr">Français</a></li><li class="interlanguage-link interwiki-ga"><a href="//ga.wikipedia.org/wiki/Siondr%C3%B3m_Guillain-Barr%C3%A9" title="Siondróm Guillain-Barré – Irish" lang="ga" hreflang="ga">Gaeilge</a></li><li class="interlanguage-link interwiki-ko"><a href="//ko.wikipedia.org/wiki/%EA%B8%B8%EB%9E%AD-%EB%B0%94%EB%A0%88_%EC%A6%9D%ED%9B%84%EA%B5%B0" title="길랭-바레 증후군 – Korean" lang="ko" hreflang="ko">한국어</a></li><li class="interlanguage-link interwiki-hr"><a href="//hr.wikipedia.org/wiki/Guillain-Barr%C3%A9ov_sindrom" title="Guillain-Barréov sindrom – Croatian" lang="hr" hreflang="hr">Hrvatski</a></li><li class="interlanguage-link interwiki-id"><a href="//id.wikipedia.org/wiki/Sindrom_Guillain%E2%80%93Barr%C3%A9" title="Sindrom Guillain–Barré – Indonesian" lang="id" hreflang="id">Bahasa Indonesia</a></li><li class="interlanguage-link interwiki-ia"><a href="//ia.wikipedia.org/wiki/Syndrome_de_Guillain-Barr%C3%A9" title="Syndrome de Guillain-Barré – Interlingua" lang="ia" hreflang="ia">Interlingua</a></li><li class="interlanguage-link interwiki-it"><a href="//it.wikipedia.org/wiki/Sindrome_di_Guillain-Barr%C3%A9" title="Sindrome di Guillain-Barré – Italian" lang="it" hreflang="it">Italiano</a></li><li class="interlanguage-link interwiki-he"><a href="//he.wikipedia.org/wiki/%D7%AA%D7%A1%D7%9E%D7%95%D7%A0%D7%AA_%D7%92%D7%99%D7%90%D7%9F-%D7%91%D7%90%D7%A8%D7%94" title="תסמונת גיאן-בארה – Hebrew" lang="he" hreflang="he">עברית</a></li><li class="interlanguage-link interwiki-lb"><a href="//lb.wikipedia.org/wiki/Guillain-Barr%C3%A9-Syndrom" title="Guillain-Barré-Syndrom – Luxembourgish" lang="lb" hreflang="lb">Lëtzebuergesch</a></li><li class="interlanguage-link interwiki-hu"><a href="//hu.wikipedia.org/wiki/Guillain%E2%80%93Barr%C3%A9-szindr%C3%B3ma" title="Guillain–Barré-szindróma – Hungarian" lang="hu" hreflang="hu">Magyar</a></li><li class="interlanguage-link interwiki-ms"><a href="//ms.wikipedia.org/wiki/Sindrom_Guillain-Barr%C3%A9" title="Sindrom Guillain-Barré – Malay" lang="ms" hreflang="ms">Bahasa Melayu</a></li><li class="interlanguage-link interwiki-nl"><a href="//nl.wikipedia.org/wiki/Syndroom_van_Guillain-Barr%C3%A9" title="Syndroom van Guillain-Barré – Dutch" lang="nl" hreflang="nl">Nederlands</a></li><li class="interlanguage-link interwiki-ja"><a href="//ja.wikipedia.org/wiki/%E3%82%AE%E3%83%A9%E3%83%B3%E3%83%BB%E3%83%90%E3%83%AC%E3%83%BC%E7%97%87%E5%80%99%E7%BE%A4" title="ギラン・バレー症候群 – Japanese" lang="ja" hreflang="ja">日本語</a></li><li class="interlanguage-link interwiki-pms"><a href="//pms.wikipedia.org/wiki/S%C3%ACndrom_%C3%ABd_Guillain-Barr%C3%A9" title="Sìndrom ëd Guillain-Barré – Piedmontese" lang="pms" hreflang="pms">Piemontèis</a></li><li class="interlanguage-link interwiki-pl"><a href="//pl.wikipedia.org/wiki/Zesp%C3%B3%C5%82_Guillaina-Barr%C3%A9go" title="Zespół Guillaina-Barrégo – Polish" lang="pl" hreflang="pl">Polski</a></li><li class="interlanguage-link interwiki-pt"><a href="//pt.wikipedia.org/wiki/S%C3%ADndrome_de_Guillain-Barr%C3%A9" title="Síndrome de Guillain-Barré – Portuguese" lang="pt" hreflang="pt">Português</a></li><li class="interlanguage-link interwiki-ru"><a href="//ru.wikipedia.org/wiki/%D0%A1%D0%B8%D0%BD%D0%B4%D1%80%D0%BE%D0%BC_%D0%93%D0%B8%D0%B9%D0%B5%D0%BD%D0%B0_%E2%80%94_%D0%91%D0%B0%D1%80%D1%80%D0%B5" title="Синдром Гийена — Барре – Russian" lang="ru" hreflang="ru">Русский</a></li><li class="interlanguage-link interwiki-simple"><a href="//simple.wikipedia.org/wiki/Guillain%E2%80%93Barr%C3%A9_syndrome" title="Guillain–Barré syndrome – Simple English" lang="simple" hreflang="simple">Simple English</a></li><li class="interlanguage-link interwiki-sl"><a href="//sl.wikipedia.org/wiki/Guillain-Barr%C3%A9jev_sindrom" title="Guillain-Barréjev sindrom – Slovenian" lang="sl" hreflang="sl">Slovenščina</a></li><li class="interlanguage-link interwiki-ckb"><a href="//ckb.wikipedia.org/wiki/%D8%B3%DB%8C%D9%86%D8%AF%D8%B1%DB%86%D9%85%DB%8C_%DA%AF%DB%8C%D9%84%DB%95%D9%86_%D8%A8%D8%A7%D8%B1%DB%8E" title="سیندرۆمی گیلەن بارێ – Central Kurdish" lang="ckb" hreflang="ckb">کوردیی ناوەندی</a></li><li class="interlanguage-link interwiki-sr"><a href="//sr.wikipedia.org/wiki/%D0%93%D0%B8%D1%98%D0%B5%D0%BD-%D0%91%D0%B0%D1%80%D0%B5%D0%BE%D0%B2_%D1%81%D0%B8%D0%BD%D0%B4%D1%80%D0%BE%D0%BC" title="Гијен-Бареов синдром – Serbian" lang="sr" hreflang="sr">Српски / srpski</a></li><li class="interlanguage-link interwiki-sh"><a href="//sh.wikipedia.org/wiki/Guillain-Barr%C3%A9ov_sindrom" title="Guillain-Barréov sindrom – Serbo-Croatian" lang="sh" hreflang="sh">Srpskohrvatski / српскохрватски</a></li><li class="interlanguage-link interwiki-fi"><a href="//fi.wikipedia.org/wiki/Guillain%E2%80%93Barr%C3%A9n_oireyhtym%C3%A4" title="Guillain–Barrén oireyhtymä – Finnish" lang="fi" hreflang="fi">Suomi</a></li><li class="interlanguage-link interwiki-sv"><a href="//sv.wikipedia.org/wiki/Guillain-Barr%C3%A9s_syndrom" title="Guillain-Barrés syndrom – Swedish" lang="sv" hreflang="sv">Svenska</a></li><li class="interlanguage-link interwiki-th"><a href="//th.wikipedia.org/wiki/%E0%B8%81%E0%B8%A5%E0%B8%B8%E0%B9%88%E0%B8%A1%E0%B8%AD%E0%B8%B2%E0%B8%81%E0%B8%B2%E0%B8%A3%E0%B8%81%E0%B8%B4%E0%B8%A5%E0%B9%81%E0%B8%A5%E0%B8%87-%E0%B8%9A%E0%B8%B2%E0%B8%A3%E0%B9%8C%E0%B9%80%E0%B8%A3" title="กลุ่มอาการกิลแลง-บาร์เร – Thai" lang="th" hreflang="th">ไทย</a></li><li class="interlanguage-link interwiki-tr"><a href="//tr.wikipedia.org/wiki/Guillain-Barr%C3%A9_sendromu" title="Guillain-Barré sendromu – Turkish" lang="tr" hreflang="tr">Türkçe</a></li><li class="interlanguage-link interwiki-uk"><a href="//uk.wikipedia.org/wiki/%D0%A1%D0%B8%D0%BD%D0%B4%D1%80%D0%BE%D0%BC_%D0%93%D1%96%D1%94%D0%BD%D0%B0_%E2%80%94_%D0%91%D0%B0%D1%80%D1%80%D0%B5" title="Синдром Гієна — Барре – Ukrainian" lang="uk" hreflang="uk">Українська</a></li><li class="interlanguage-link interwiki-vi"><a href="//vi.wikipedia.org/wiki/H%E1%BB%99i_ch%E1%BB%A9ng_Guillain-Barr%C3%A9" title="Hội chứng Guillain-Barré – Vietnamese" lang="vi" hreflang="vi">Tiếng Việt</a></li><li class="interlanguage-link interwiki-zh-yue"><a href="//zh-yue.wikipedia.org/wiki/%E5%90%89%E5%B7%B4%E6%B0%8F%E7%B6%9C%E5%90%88%E7%97%87" title="吉巴氏綜合症 – Cantonese" lang="zh-yue" hreflang="zh-yue">粵語</a></li><li class="interlanguage-link interwiki-zh"><a href="//zh.wikipedia.org/wiki/%E6%A0%BC%E6%9E%97%EF%BC%8D%E5%B7%B4%E5%88%A9%E7%BB%BC%E5%90%88%E5%BE%81" title="格林－巴利综合征 – Chinese" lang="zh" hreflang="zh">中文</a></li><li class="uls-p-lang-dummy"><a href="#"></a></li>					</ul>
				<div class='after-portlet after-portlet-lang'><span class="wb-langlinks-edit wb-langlinks-link"><a href="//www.wikidata.org/wiki/Q205214#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></span></div>			</div>
		</div>
				</div>
		</div>
		<div id="footer" role="contentinfo">
							<ul id="footer-info">
											<li id="footer-info-lastmod"> This page was last modified on 11 July 2015, at 14:32.</li>
											<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License</a><a rel="license" href="//creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="//wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="//wikimediafoundation.org/wiki/Privacy_policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
									</ul>
							<ul id="footer-places">
											<li id="footer-places-privacy"><a href="//wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
											<li id="footer-places-about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
											<li id="footer-places-disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
											<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
											<li id="footer-places-developers"><a href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
											<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Guillain%E2%80%93Barr%C3%A9_syndrome&amp;mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
									</ul>
										<ul id="footer-icons" class="noprint">
											<li id="footer-copyrightico">
							<a href="//wikimediafoundation.org/"><img src="/static/images/wikimedia-button.png" srcset="/static/images/wikimedia-button-1.5x.png 1.5x, /static/images/wikimedia-button-2x.png 2x" width="88" height="31" alt="Wikimedia Foundation"/></a>						</li>
											<li id="footer-poweredbyico">
							<a href="//www.mediawiki.org/"><img src="//en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="//en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_132x47.png 1.5x, //en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" /></a>						</li>
									</ul>
						<div style="clear:both"></div>
		</div>
		<script>if(window.jQuery)jQuery.ready();</script><script>if(window.mw){
mw.loader.state({"ext.globalCssJs.site":"ready","ext.globalCssJs.user":"ready","site":"loading","user":"ready","user.groups":"ready"});
}</script>
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=ext.cite.styles%7Cext.gadget.DRN-wizard%2CReferenceTooltips%2CWatchlistGreenIndicators%2Ccharinsert%2Cfeatured-articles-links%2CrefToolbar%2Cswitcher%2Cteahouse%7Cext.wikimediaBadges&amp;only=styles&amp;skin=vector&amp;*" />
<script>if(window.mw){
mw.loader.load(["ext.cite.a11y","mediawiki.toc","mediawiki.action.view.postEdit","mediawiki.user","mediawiki.hidpi","mediawiki.page.ready","mediawiki.searchSuggest","ext.cirrusSearch.loggingSchema","mmv.bootstrap.autostart","ext.imageMetrics.loader","ext.eventLogging.subscriber","ext.wikimediaEvents","ext.wikimediaEvents.statsd","ext.navigationTiming","ext.gadget.teahouse","ext.gadget.ReferenceTooltips","ext.gadget.WatchlistGreenIndicators","ext.gadget.DRN-wizard","ext.gadget.charinsert","ext.gadget.refToolbar","ext.gadget.switcher","ext.gadget.featured-articles-links","ext.visualEditor.targetLoader","schema.UniversalLanguageSelector","ext.uls.eventlogger","ext.uls.interlanguage"],null,true);
}</script>
<script>if(window.mw){
document.write("\u003Cscript src=\"//en.wikipedia.org/w/load.php?debug=false\u0026amp;lang=en\u0026amp;modules=site\u0026amp;only=scripts\u0026amp;skin=vector\u0026amp;*\"\u003E\u003C/script\u003E");
}</script>
<script>if(window.mw){
mw.config.set({"wgBackendResponseTime":150,"wgHostname":"mw1044"});
}</script>
	</body>
</html>
